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Summary 
 
Triggering receptor expressed on myeloid cells-2 (TREM2) is an innate immune receptor, 
which is expressed on myeloid cells, like microglia inside the central nervous system. TREM2 
signals via the adaptor protein DAP12. Previous studies have suggested that TREM2 plays a 
protective role in neuroinflammatory diseases. Activation of TREM2 increases phagocytosis 
and decreases pro-inflammatory microglial responses in vitro. However, the ligand which 
specifically binds to TREM2 is still unknown. Main objectives of this study were to find out 
structural elements recognized by TREM2 and to elucidate the effects of TREM2 ligand 
binding in microglia. 
To identify possible ligands for TREM2; human glioblastoma cells (U87), mouse glioma cells 
(GL261), small-cell lung carcinoma (SMA-560) and Chinese hamster ovary cells (CHO) were 
incubated with a TREM2b-Fc-fusion protein. Binding of TREM2 to target cells was blocked 
with different polysaccharides. Binding strength under different conditions was analysed by 
flow cytometry.  
First, TREM2b-Fc-fusion protein bound CHO, GL261, SMA-MS and U87 cells. Furthermore, 
these results show that the binding of the TREM2b-Fc fusion protein to U87 cells can be 
blocked at different efficiencies by the following glycosaminoglycans: dextran sulfate, 
chondroitin sulfatecontaining all subtypes of chondrotin suflates, chondroitin sulfate A (CS-A, 
chondroitin-4-sulfate), and adequan (polysulfated glycosaminoglycan), but not by chondroitin 
sulfate C (chondroitin-6-sulfate). As a control, U87 cells were pretreated with chondroitinase 
ABC. In line with the former results the binding of the TREM2b-Fc-fusion protein to the cells 
was reduced after removal of chondroitin sulfates from the glycocalyx of the target cells. 
These results confirm chondrotin suflates as ligands for TREM2 receptor. In contrast, 
pretreatment of U87 cells with sialidase (removal of sialic acids) did not change the binding of 
TREM2b-Fc-fusion protein. CS-A as an endogenous brain-derived molecule showed efficient 
binding and was selected as promising stimulating ligand for TREM2 in further experiments.  
Next, expression of TREM2 in a mouse microglia cell line was confirmed and the effects of 
CS-A and the core disaccharide unit of CS-A were analyzed. Treatment of TREM2 receptor 
expressing microglia with CS-A and the CS disaccharide stimulated phagocytosis of beads. 
On the other hand, the lentiviral knockdown of TREM2 in mouse microglia decreased the 
phagocytosis of beads after stimulation with 2 mM CS-A or 0.2 mM chondroitin sulfate 
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disaccharides DS-4S. Stimulation of microglial cells with CS-A led to an up-regulation of 
pro-inflammatory cytokines (IL-1ß and TNF-α) and a down-regulation of iNOS. While 
stimulation of microglial cells with DS-4S led to a down-regulation of pro-inflammatory 
cytokines (IL-1ß, TNF-α and iNOS).  
In summary, these results suggest a new ligand for TREM2. Upon TREM2 stimulation by CS 
A or DS-4S, microglial cells are phagocytically activated. Taken together, these results 
suggest a protective role for TREM2 in the central nervous system. 
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1. Introduction 
1.1 Microglia 
Microglia, the resident immune cell of the CNS, were first described in 1919 by Pío del Río 
Hortega (del Rio Hortega, 1919).  As suggested by their name, microglia are very small 
compared to other glia in the CNS and have a heterochromatic nucleus (Fig. 1.1). Microglia 
have crucial importance for development, defense and regulation of CNS. During the 
development of the CNS, microglia are important in axonal pruning as well as in the clearance 
of debris and apoptotic cells (Zacharchuk et al., 1990; Ewers et al., 1996; Mallat et al., 2005). 
Microglia play a role in protection of the immune-privileged CNS against foreign pathogens 
and as the resident immune cells, they are the first line of defense. They are found throughout 
in the adult brain and comprise about 10 % of all brain cells  (Ransohoff and Perry, 2009).  
 
Microglial processes are motile which allow them to monitor the environment and respond by 
changing their morphology and genetic expression profile (Davalos et al., 2005; Dudziak et 
al., 2005). Microglia can also move within CNS and migrate in response to tissue damage or 
towards specific chemoattractants released by damaged cells (Blade et al., 2005).  
 
However, microglial cells can also produce neurotrophic and neuroprotective molecules such 
as nerve growth factor (NGF), indicating a role in neuronal survival, in cases of brain injury. 
Therefore, they are considered to have a double-edged nature, as they have both beneficial 
and detrimental effects.  
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The origin of resident microglia in the CNS was controversial for many years. In the early 
1900s microglia were thought to be of neuroectodermal origin because of its location in the 
CNS. However, microglia bears certain similarities to cells of the mononuclear phagocyte 
lineage which exist in other tissues. Indeed, after decades of debate, it is now proven that 
microglia are of haematopoietic origin and that they are derived from myeloid progenitors 
from the yolk sac during early development (Fig. 1.2)  (Ng et al., 1993; Raivich et al., 1996).  
The microglial progenitors cells, which originate from the yolk sac, migrate to the central 
nervous system (CNS) and develop into early microglia cells (Ginhoux et al., 2010). Another 
study showed that the microglia can be detected during the development of the CNS in 
rodents as early as around embryonic days (E8-9), (Hickey and Kimura, 1988). During the 
last years, evidence arouse that resident microglia emerge through primitive yolk sac 
macrophages derived from haematopoietic stem cells via a myeloid progenitor state  (Fig.1.2) 
(Ginhoux et al., 2010). 
 
A subset of microglia is derived from bone marrow monocytes, though it has been shown   
that the transition is a rare event and takes place only under irradiation, lesion or inflammation 
(Mildner et al., 2007; Kigerl et al., 2009; Shechter et al., 2009). In addition, Ajami et al have 
recently shown that blood-derived monocytes infiltrating the brain during experimental 
autoimmune encephalomyelitis (EAE) do not contribute to the resident microglia in the CNS 
(Ajami et al.; Mildner et al., 2007).  
Figure 1.1 - Left: Drawing of ramiedied microglia by del Rio Hortega (del Rio Hortega, 1919). 
Right: Photomicrograph of silver stained microglia (del Rio Hortega, 1932). 
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These findings go along with older publications which have already shown that yolk sac 
macrophages can  proliferate after migrating into the embryonic tissue (Cossmann et al., 
1997).  
Microglia may be activated by a whole set of structurally unrelated compounds and 
molecules. Microglia is activated in infectious diseases of the CNS and pathogen components 
activate microglia in vitro (Chi et al., 2001). Microglia detect pathogens by means of pattern 
recognition receptors (PRRs) on the cell surface, which recognize so-called pathogen-
associated molecular patterns (PAMPs), molecular structures associated with pathogens but 
not with host cells (Xu et al., 2000). Most PRRs are expressed only at low levels on ramified 
microglia, if at all, and are upregulated upon microglial activation (Chi et al., 2001), and after 
microglia are activated can have phagocytic capacity ant that is associated with increased release 
of cytokines and expression of  receptors and major histocompatibility complex (MHC) antigens, and 
in the adult brain microglia can switch inbetween two states (Fig. 1.3). 
 
Figure 1.2 - Origin of microglia. Cells from hematopoietic origin and central nervous system are 
illustrated. The differentiated cells are marked with arrows. Microglia is the only hematopoietic cell 
found in the parenchyma of the CNS. modified from Ransohoff & Cardona, 2010.  
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The most commonly used compound to stimulate microglial activation experimentally in vitro 
and in vivo is the bacterial endotoxin lipopolysaccharide (LPS), which is a major component 
of the outer membrane of gram-negative bacteria (Rietschel and Kimmig, 1994). In addition, 
microglial receptors initiate phagocytosis of other pathogens which have been opsonised 
(coated) by soluble components of the immune system (Chi et al., 2001).  
 
Microglia reacts rapidly to local tissue damage, suggesting that a signal from damaged cells 
can be sufficient to activate microglia (Gehrmann et al., 1991; Morioka et al., 1992). 
Accordingly, large amounts of ATP that is released mainly by astrocytes under pathological 
conditions (Ciccarelli et al., 2001) were shown in vitro to affect microglial morphology 
(Honda et al., 2001) as they cause elevation of intracellular Ca2+ (McLarnon et al., 1999),  
release of cytokines, and activate chemotactic effects (Honda et al., 2001; Davalos et al., 
2005). These effects, characteristic of microglial activation, may be mediated via the 
activation of P2Y purinergic receptor (Honda et al., 2001; Davalos et al., 2005), or opening 
P2X7 ATP-gated ion channel (Monif et al., 2009). Elevated extracellular K+, also indicative 
Figure 1.3 – Resting and activated microglia state (Perry et al., 2007). 
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of tissue damage, depolarizes the membrane potential of microglia and can initiate microglial 
activation (Colton et al., 1994; Abraham et al., 2001). In addition, inwardly-rectifying K+ 
channels expressed by microglia (Kettenmann et al., 1990; Norenberg et al., 1994), current 
through which is enhanced under conditions of elevated K+, may be involved in cytokine-
dependent proliferation and differentiation of microglial cells (Schlichter et al., 1996; Shirihai 
et al., 1996). 
Like cells of the mononuclear phagocyte lineage, microglia is also capable of phagocytosing 
pathogens (Giulian and Baker, 1986; Streit et al., 1988; Rieske et al., 1989). State when the 
cells are amoeboid and migratory. Phagocytosis of pathogen components and subsequent  
processing leads to the presentation of antigens by the major histocompatibility complex 
(MHC) molecules, which are required for T cell activation (Cash et al., 1993). This is 
accompanied by an upregulation of other molecules associated with activation, including a 
number of cell adhesion molecules, which allow microglia to further detect and internalize 
diverse material (Raivich et al., 1999). This removal of apoptotic cells and debris is important 
in maintaining homeostasis of the CNS. Moreover, the process of phagocytosis induces a 
general pro-inflammatory phenotype in the microglia.  
The main pathway of communication between microglia and other cells of the immune 
system is through the cytokine system. Microglia expresses cytokines and their receptors and 
release cytokines (including chemokines) to its environments. This can mediate recruitment of 
further microglia and peripheral immune cells, and initiate activation of such cells. Cytokines 
can be grouped as pro–inflammatory and anti-inflammatory cytokines (Kettenmann et al.; 
Biber et al., 2007).  
IFN-γ (Interferron gamma) appears to amplify the pro-inflammatory effects of microglial 
activators (Colton, 1994; Hausler et al., 2002) and is often used in vitro as a co-stimulator for 
LPS-mediated activation. Microglia expresses receptors for the lymphocyte-derived cytokine 
interferon-gamma (IFN-gamma) and respond to it both in vitro and in vivo with an 
upregulation in microglial expression of MHC molecules, suggesting enhanced antigen 
presenting ability (Vass and Lassmann, 1990; Loughlin et al., 1992; Panek and Benveniste, 
1995; Deckert-Schluter et al., 1999).  
The effects of anti-inflammatory cytokines can be largely attributed to the downregulation of 
pro-inflammatory cytokines or functional antagonism of their effects (Hanisch, 2002). For 
example, LPS has been shown to induce transforming growth factor β (TGFβ) production by 
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microglia, through a tumour necrosis factor α (TNF-α) dependent pathway. Since TGFβ was 
shown to inhibit LPS-stimulated TNFα production (Chao et al., 1995) a self-regulating 
mechanism can be assumed to exist, with the potential to control inflammation (Choi et al., 
2003). 
Different microglial receptors and signaling pathways are involved in the detection of and 
response to different molecules which activate microglia (Pocock and Liddle, 2001). 
Therefore, it is likely that different microglial activators cause the upregulation of specific 
genes which are leading to slightly different activated phenotypes. Microglial activation leads 
to the expression of the so-called death receptor, Fas/CD95 and its ligand FasL/CD95L. This 
induces the release of reactive oxygen and nitrogen species (ROS), proteolytic enzymes, 
prostanoids and glutamate. Also, activated microglia expresses inducible nitric oxide synthase 
(iNOS), which allow the production of the vasodilator and non-specific inflammatory 
mediator nitric oxide (NO) from L-arginine (Chao et al., 1992; Ding et al., 1997; Possel et al., 
2000).  
1.2 Triggering receptor expressed on myeloid cells-2 (TREM2) 
In the CNS, the innate and adaptive immune responses are strongly reduced, but when have 
some damage, due to chronic, Triggering receptor expressed on myeloid cells 2 (TREM2) is 
an innate immune receptor and has an immunoglobulin superfamily domain in their 
extracellular part with a charged lysine residue in their transmembrane domain. They have 
also a short cytoplasmatic tail that associates signaling molecule DAP12 containing an ITAM 
(immunoreceptor tyrosine-based activation motif) (Colonna, 2003), (Fig. 1.4). 
TREM2 is expressed on myeloid origin cells such as  immature dendritic cells, osteoclasts and 
microglia (Colonna, 2003). In human, TREM2 is expressed on microglia and a subpopulation 
of neurons (Sessa et al., 2004). A study using a systemic screen for gene transcripts 
selectively expressed on resting microglia versus activated microglia/macrophages, was the 
first to demonstrate TREM2 expression on microglia (Schmid et al., 2002). The same group 
has shown microglial TREM2 receptor was down-regulated after inflammatory stimulus with 
LPS/IFNgammaLPSLPS/IFNgammaIFNγ (Schmid et al., 2002). TREM2 signaling after 
ligation with agonistic monoclonal antibodies on immature dendritic cells has been shown to 
stimulate maturation and up-regulation of the chemokine receptor CCR7 and some co-
stimulatory molecules (Bouchon et al., 2001). Consequently in microglial cells, TREM2 
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signaling via the adaptor molecule DAP12 stimulates the protein tyrosine kinase ERK 
(Takahashi et al., 2005). Furthermore, TREM2 can regulate the migratory capacity of 
microglia (Takahashi et al., 2005). Studies have shown that the tyrosine residues within the 
immunoreceptor  ITAM of the adaptor molecules DAP12 or FcR gamma were required for 
the inhibitory signaling and the anti-inflammatory signaling of TREM2 in microglia 
(Neumann and Takahashi, 2007). This would be in line with a novel inhibitory signaling 
function of the ITAM-containing adaptor molecule DAP12 (Neumann and Takahashi, 2007). 
TREM2 and DAP12 mutations are leading to Nasu-Hakola disease (see next chapters). 
 However, apoptotic neural cell membranes are capable to stimulate the TREM2 receptor of 
microglia, but it is unclear which nervous tissue derived ligand binds to the TREM2 receptor. 
Extracellular region of mouse TREM2 can bind to bacteria, yeast and bacterial products and 
binding can blocked by anionic carbohydrate molecules, including dextran sulfate, where 
TREM2 might function as a sort of scavenger receptor for polyanionic macromolecules 
(Colonna, 2003; Stefano et al., 2009). Furthermore, the discovery of the ligands for TREM2 
receptor will be crucial to verify these beneficial hypotheses and to characterize precisely the 
contribution of TREM2 receptor to immune and non-immune functions in different 
neurological diseases. 
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Figure 1.4 - TREM2 signalling cascades after binding of ligand. TREM2 receptor is 
completely dependent on ITAM domain-containing DAP12. Receptor-domain interaction 
occurs between charged amino acids (+/-) in their transmembranes regions. Ligand binding to 
TREM2 induces the formation of multivalent ligand-receptor complexes that trigger full 
phosphorylation of immunoreceptor tyrosine-based activation motifs (ITAMs) and 
recruitment of SYK and MAP, mitogen-activated protein kinase. This results in actin 
cytoeskeleton reorganization and increase of phagocytosis. SYK- spleen tyrosine kinase, 
PLCɣ - phospholipase C-ɣ, PI3K – phosphotidylinositol 3-kinases, LAT – linker for 
activation of T cells, TREM2 – triggering receptor expression on myeloid cells 2. Modified 
from (Linnartz and Neumann, 2013). 
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1.2.1 TREM2 function of primary mouse microglia 
It,  in vitro studies have described TREM2 is a microglial innate immune receptor for 
phagocytosis of apoptotic neurons (Takahashi et al., 2005). They showed gene transcription 
and protein expression of TREM2 in cultured murine microglia by RT-PCR and 
immunohistochemistry, respectively. Stimulation of TREM2 by cross-linking antibodies 
induced DAP12 phosphorylation, extracellular signal-regulated kinase phosphorylation, and 
cytoskeleton reorganization (Takahashi et al., 2005). Furthermore, TREM2 stimulation 
induced phagocytosis of apoptotic material and beads. Knockdown of TREM2 in microglia 
inhibited phagocytosis of apoptotic neurons and increased gene transcription of tumor 
necrosis factor-alpha (TNF-alpha) and nitric oxide synthase-2 (NOS2), whereas over-
expression of TREM2 increased phagocytosis and decreased microglial pro-inflammatory 
responses. Thus, TREM2 deficiency of microglia in vitro resulted in impaired clearance of 
apoptotic neurons and inflammation. Cross-linking of TREM2 on primary microglia by a 
monoclonal antibody did not modulate constitutive gene transcription of TNF-alpha, 
interleukin-1beta (IL-1beta) and NOS2 (Takahashi et al., 2005). However, stimulation of 
TREM2 by cross-linking antibodies counter-regulated induction of inflammatory mediators 
by TLR-stimulation that is also regularly seen in damaged tissue.  
1.2.2 Microglial TREM2 is a beneficial phagocytic receptor for silent clearance of 
apoptotic bodies 
TREM2 is a phagocytic receptor that promotes the clearance of apoptotic material by 
microglia and favors anti-inflammatory cytokine signaling (Takahashi et al., 2005). The 
TREM2/DAP12 deficiency impairs the clearance of debris arising from sporadic neuronal 
death. The ensuing accumulation of apoptotic material induces the activation of microglial 
cells that are no longer alleviated by TREM2/DAP12 and produce neurotoxic pro-
inflammatory mediators, inducing further neuronal death and more apoptotic debris 
(Neumann and Takahashi, 2007). In agreement with a beneficial role of the native microglial 
TREM2, the laboratory of Professor Neumann established that transfer of myeloid precursor 
cells transduced with TREM2 ameliorated the disease course of experimental autoimmune 
encephalomyelitis (EAE) (Takahashi et al., 2007). Likewise, blockade of TREM-2 by an 
antibody exacerbates experimental autoimmune encephalomyelitis (Piccio et al., 2007).  
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The ligand of TREM2 is still poorly defined. TREM2 was shown to be a pattern recognition 
receptor that binds to anionic carbohydrates (Daws et al., 2003) and Hsp60 displayed by 
damaged cells (Stefano et al., 2009). The detailed characterization of the TREM2 ligands will 
be an important step to have a candidate molecule for a novel therapy. 
1.2.3 Loss of TREM2 function is leading to a monogenic rare disease with presenile 
dementia and bone alterations 
Nasu-Hakola disease (NHD) - also known as polycystic lipomembranous osteodysplasia with 
sclerosing leukoencephalopathy is a genetic disorder due to loss-of function mutations in the 
genes encoding either the TREM2 or its signaling adapter molecule DAP12 (Paloneva et al., 
2000). In the brain, expression of DAP12 and TREM2 or their mutated forms are exquisitely 
restricted to microglia (Paloneva et al., 2001; Roumier et al., 2004; Sessa et al., 2004; 
Takahashi et al., 2005; Roumier et al., 2008; Wakselman et al., 2008; Thrash et al., 2009). 
Therefore, the primary cause of NHD can only be an alteration of microglial DAP12/TREM2 
function. NHD patients suffer from bone alterations and presenile dementia and death, 
occuring in the early 40s (Paloneva et al., 2001).  
Patients show advanced loss of axons and myelin with axonal spheroids in the frontal and 
temporal lobes (Paloneva et al., 2000). The most remarkable microscopic alterations are 
astrogliosis and strong microglial activation in the cerebral white matter lobes (Paloneva et 
al., 2001). Mouse models of NHD have been obtained by mutating or deleting the TREM2 
and DAP12 genes (Tomasello et al., 2000; Turnbull et al., 2006). In contrast to other mouse 
models of genetic diseases, DAP12-mutated mice recapitulate several of the human 
symptoms. For instance, DAP12-mutated mice display bone and white matter alterations 
(Kaifu et al., 2003; Nataf et al., 2005) that are mainly detected at late adulthood (Kaifu et al., 
2003). The brain phenotype of TREM2 deficient mice has not been described so far.  
1.2.4 TREM2 and Neurodegenerative Disease 
Recently an association between the single-nucleotide polymorphism (SNP) rs75932628 in 
the gene enconding the TREM2 (predicting an R47H substitution) and Alzheimer´s disease in 
persons of European ancestry was described (Guerreiro et al., 2013; Jonsson et al., 2013). 
Alzheimer´s disease is a genetically heterogeneous disorder characterized by the coexistence 
of monogenic and genetically complex forms. The variant R47H of TREM2 roughly triples 
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the lifetime risk to develop Alzheimer´s disease, but the frequency of this risk variant was 
reported to be only 0.63% in the Iceland population and somewhat variable across other 
European populations (Benitez et al., 2011). Another group analyzed how the gene variant 
(risk allele of rs9394721) affects the risk of Alzheimer´s disease by mapping its effect on the 
brain by brain magnetic resonance imaging (MRI) in temporal lobes. Then, they demonstrated 
that the annual rates of brain-volume loss over time in this region were associated with 
carrying the risk allele of rs9394721, a close proxy for the newly discovered risk variant 
rs75932628 in TREM2 (Hua et al., 2010). 
Several other observations supported that TREM2 variation may confer susceptibility to 
fromtotemporal dementia and Parkinson´s disease. Microgliosis has been implicated in the 
pathogenesis of Parkinson´s disease, a neurologic disorder characterized by degeneration of 
dopaminergic neurons in the substantia nigra pars compacta, dopaminergic neurons express 
ligands that interact directly with TREM2, and TREM2 messenger RNA levels in the 
substancia nigra are the second highest among all brain regions. In addition, pathological 
findings in TREM2 variant carriers have shown the presence of abundant Lewy bodies, a 
hallmark of Parkinson´s disease (Hsieh et al., 2009). 
The TREM2 risk variant may affect signaling by TREM2 receptors expressed on microglial 
cells in the brain, perhaps interfering with anti-inflammatory functions of these cells and their 
removal of apoptotic tissue.  
1.3 Glycosaminoglycans family and classification 
The glycosaminoglycans (GAGs) are know to play critical functions in CNS, include 
inhibition of axonal growth and regeneration, neuritogenic activity, and pathogens infections, 
the GAGs are the more component of extracellular matrix (Sugahara et al., 2003). GAGs are 
found many tissues in the cornea, where they are known to regulate neurite growth, regule 
embryo implantation in the endometrial uterine living during menstrual endothelial cells and 
also are envolved with tumor progression tumor metastasis, and pathological reparative 
processes (Laurent et al., 1996; Funderburgh, 2000). 
Glycosaminoglycans are linear, sulfated, negatively charged polysaccharides that have 
molecular weights of rougly 10-100kDa. There are two main types of GAGs. Non-sulfated 
GAGs include hyaluronic acid (HA), whereas sulfated GAGs include chondroitin sulfate 
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(CS), dermatan sulfate (DS), keratin sulfate (KS), heparin and heparin sulfate (HS) 
(Rademacher et al., 1988) and the focus of this work is investigate that CS can binding to 
TREM2 receptor. 
 
Table 1.1 - Repeating disaccharide units of various Glycosaminoglycans family. 
Modified from (Sasisekharan et al., 2006) 
Glycosaminoglycans Dissacharides 
Units 
Features 
Hyaluronic acid D-GlcA-β(1 – 4) 
D-GlcNAc-α(1-4) 
• Molecular weight 4- 800 kDa. 
• Non-sulfated non-covalently 
attached to proteins in the ECM; 
also found in bacteria. 
Chondroitin sulphate 
• Usually found in synovial fluid, 
vitreous humour, ECM of loose 
connective tissue. 
• Excellent lubricators and shock 
absorbers. 
Chondroitin sulfate D-GlcA-β(1-3) 
DGalNAc4S-β(1-4) 
• Molecular weight 5-50 kDa. 
• Most abundant GAG in the body 
found in cartilage, tendon, 
ligament, aorta. 
• Binds to proteins (like collagen) 
to form proteoglycan aggregates. 
Dermatan sulfate L-IdoA-α(1-3)-D-
GalNAc4S-β(1-4) 
• Molecular weight 15-40 kDa. 
• Found in skin, blood vessels, 
heart valves 
Karatan sulfates I 
and II 
D-Gal-β(1-4)-D-
GalNAc6S-β(1-3) 
• Molecular weight 4-19 kDa. 
• Most heterogeneous GAG. 
• KS I is found in the cornea. 
• KS II is found in cartilage 
aggregated with CS. 
 
 
Glycosaminoglycans chains are composed of disaccharide repeating units called disaccharide 
repeating regions (table 1.1), the repeating units are composed of uronic acid (D-glucoronic 
acid or L-iduronic acid) and amino sugar (D-galactosamine or D-glucosamine). Hence, GAGs 
differ according to the type of hexosamine, hexose or hexuronic acid unit that they contain. 
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Chondroitin sulphate and DS, which contain galactosamine, are called galactosaminoglycans, 
whereas heparin and HS, which contain glucosamine, are called glucosaminoglycans. The 
amino sugar may be sulphated on carbon 4 or 6 or on the non-acetylated nitrogen; however, 
the sugar backbone of GAGs can be sulfated at various positions (Rademacher et al., 1988).  
Glycosaminoglycans are large complex carbohydrate molecules that interact with a wide 
range of proteins involved in physiological and pathological processes in cell adhesion, cell 
growth and differentiation, cell signaling anticoagulation (Jackson et al., 1991; Casu and 
Lindahl, 2001). 
1.3.1 The role of glycosaminoglycans in the central nervous system 
Chondroitin sulfate proteoglycans (CSPGs) consist of a core protein and they are found in 
extracellular matrix of all cell surface and also in CNS. Most of the CSPGs are secreted from 
cells and participate in the formation of the extracellular matrix. CSPG are can find attached 
to matrix protein occurs naturally in the central nervous system, is considered to be a major 
inhibitor of axonal regeneration and is known to participate in activation of inflammatory 
response (Rolls et al., 2006).  
In the normal central nervous system, CSPGs have a role in development and plasticity during 
postnatal development and in the adult brain. In the adult, CSPGs play a part in learning and 
memory. They are also involved in the hypothalamo-neurohypophysial system and also have 
an important role in CNS injuries and diseases. After CNS injury, CSPGs are the major 
inhibitory component of the glial scar. Removal of CSPGs improves axonal regeneration and 
functional recovery. CSPGs may also be involved in the pathological processes in diseases, it 
is up-regulated after CNS injury and during the course of chronic neurodegenerative disorders 
such as epilepsy, stroke, Alzheimer´s disease and multiple sclerosis disorders (Viapiano and 
Matthews, 2006). 
The roles of CSPGs in Alzheimer´s disease appear to be multiple. The CSPGs colocalize with 
both amyloid plaques and neurofibrillary tangles suggesting either that they could be 
instrumental in the formation of these deposits or that they are a reaction to them (DeWitt et 
al., 1993; McLaurin and Fraser, 2000). In vitro studies demonstrated that CSPGs and GAGs 
promote Aß fibril formation and binding of GAGs to Aß. It has been shown that CSPGs 
inhibit the proteolysis of Aß fibrils (Gupta-Bansal et al., 1995). Aß is a very strong stimulant 
to astrocytic CSPGs production and these CSPGs are particularly inhibitory to neuronal 
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process outgrowth and may facilitate the decreased axon density and synaptic loss in human 
Alzheimer´s disease brain (DeWitt et al., 1994; DeWitt and Silver, 1996). How chondroitin 
sulfate might control neuroinflammation is still unclear. 
1.3.2 The structure of chondroitin Sulfate proteoglycans in central nervous system 
Chondroitin sulfate glycosaminoglycans (CS-GAGs) are long, linear chains that are formed 
by repeating disaccharide units (Brooks et al., 2002), can be found also distribuited in the 
CNS. The disaccharides are polymerized into long chains by the recently identified human 
chondroitin synthase (Kitagawa et al., 2001) and the protein chondroitin polymerizing factors 
(Kitagawa et al., 2003). The chondroitin sulfates are then modified by sulfation and the 
positions of sulfation define the type of CS (Properzi et al., 2003). The CS disaccharides can 
be monosulfated in the 4 or 6 position of the GalNAc residue (CS-A and CS-C, respectively) 
or disulfated in the 2 and 6 position of the GalNAc, respectively (CS-D), and in the 4 and 6 
position of the GalNAc (CS-E) (Fig. 1.5)  and the terminology of CS group in table 1.2 
(Sugahara et al., 2003) (Table 1.2).  
It has been shown that the disaccharidic (DS) products of CSPG degradation; 6-sulfated 
disaccharide(CSPG-DS), induces axonal growth and activates microglia to adopt a 
neuroprotective phenotype (Rolls et al., 2004). Other work in literature demonstrate that 
disacharidic degradation product of this glycoprotein (CSPGDS) participate in the modulation 
of the inflammatory responses and can, therefore, promote recovery in immune-induced 
neuropathologies of the CNS, such as experimental autoimmune encephalomyelitis (EAE) 
and experiemntal autoimmune uveitis (EAU). It was shown that CSPGDS markedly alleviated 
the clinical symptoms of EAE and attenuated T cell motility. Furthermore, they decrease 
secretion of the cytokines interferon-gamma and tumor necrosis factor-alpha (Rolls and 
Schwartz, 2006). Literature shows that treatment of the visual cortex of adolescent rats at 
postnatal day P70 with ChABC (chondroitnase sulfate ABC, an enzyme from the bacteria 
Proteus vulgaris, that catalyzes the removal of CS-GAG chains of CSPGs) (Prabhakar et al., 
2005) showed reactivation of ocular dominance plasticity after the critical period (Pizzorusso 
et al., 2002). However, other studies suggest that ChABC drive normalization of ocular 
dominance, visual acuity and dendritic spine density in the adult rats as shown by anatomical, 
electrophysiological and behavioral methods (Pizzorusso et al., 2006). 
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Other works show that administration of CSPG-DS, but not CS-A, in mice, after onset of 
clinical symptoms of EAE, was able to suppress the disease. Further studies demonstrated that 
CS-A up-regulated STAT3 and IL-23 expression and thus increased IL-17 producing T cells 
induceing a Th1 response. CSPG-DS treatment both in vivo and in vitro decreased TNF-alpha 
production from splenocytes. In vitro and in vivo studies indicated that CSPG-DS treatment in 
EAE mice significantly blocked migration of lymphocytes. Whereas CS-A increased 
lymphocyte infiltration in the mice brain and induced Th1 response (Zhou et al.). 
 
Table 1.2 - Terminology of chondroitin sulfate group. 
Letter identification Site of sulfation Systematic name 
Chondroitin Sulfate   carbon 4 of the N-
acetylgalactosamine 
(GalNAc) sugar 
 
 carbon 6 of the 
GalNAc sugar 
 
 
 carbon 2 of the 
glucuronic acid and 6 
of the GalNAc sugar 
 
 carbons 4 and 6 of the 
GalNAc sugar 
 
Chondroitin sulfate 4 – 6 -2,6 
-4 ,6 sulfate 
Chondroitin sulfate A  carbon 4 of the N-
acetylgalactosamine 
(GalNAc) sugar 
Chondroitin-4-sulfate 
Chondroitin sulfate C  carbon 6 of the 
GalNAc sugar 
Chondroitin-6-sulfate 
Chondroitin sulfate D  carbon 2 of the 
glucuronic acid and 6 
of the GalNAc sugar 
Chondroitin-2,6-sulfate 
Chondroitin sulfate E  carbons 4 and 6 of the 
GalNAc sugar 
Chondroitin-4,6-sulfate 
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Figure 1.5 - Structures of chondroitin sulfate family and chondroitinase ABC digestion. 
  Aim   
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2. Aim 
Triggering receptor expressed in myeloid (TREM) cells 2, a receptor expressed by myeloid 
cells, osteoclasts and microglia, is known to play a protective role in bones and brain. 
Mutations of the receptor or of its coupling protein, DAP12 sustain in fact a genetic disease 
affecting the two organs, the polycystic lipomembraneous osteodysplasia with sclerosing 
leukoencephalopathy (PLOSL or Nasu-Hakola disease). So far, specific agonist(s) of TREM2 
have not been identified, and that ligands can binds to TREM2 are largely unknown. Heat 
shock protein 60 (Hsp60) is a mitochondrial chaperone  is already been shown can binds to 
TREM2 (Stefano et al., 2009), and another work showed that TREM-2 binds to 
lipooligosaccharides of Neisseria gonorrhoeae and is expressed on reproductive tract 
epithelial cells (Quan et al., 2008).  
However, the present thesis proposes to find specifics structures can be recognize by TREM2 
receptor. 
The first aim is try to identify of activating anionic polysaccharides binding to TREM2. 
Specific agonists of TREM2 have not been identified so far. Anionic polysaccharides with 
binding specificity to TREM2 and containing a high number of polymers (> 30 saccharides) 
might have the capacity to cross-link two or several TREM2 receptors, thus stimulating the 
signaling cascade. Anionic polysaccharides from different sources and different degrees of 
polymerization were tested by blocking the binding of a TREM2-Fc-fusion protein to the 
glycocalyx of altered cells (e.g. glioma cells).   
The second aim is to investigate TREM2 function in mouse microglial line. Furthermore, the 
anionic polysaccharides should be tested in their capacity to stimulate TREM2 function such 
as phagocytosis in cultured mouse microglia with a normal or knockeddown expression of 
TREM2. Recently, the laboratory of Dr. Neumann established a protocol for the 
differentiation of mouse embryonic stem cells to microglia cells (ESdM). The differented 
mouse microglial cells were transduced with lentivirus to knockdown TREM2 using shRNA. 
Cells were challenged with chondroitin sulfate or disaccharide sulfate or not sulfated 
disaccharides. Phagocytic activity was monitored by flow cytometry analysis and 
inflammatory gene transcripts of microglia were determined by RT-PCR. 
Results  
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3. Materials and Methods: 
3.1 Materials 
3.1.1 Buffers and Solutions 
 
Table 3.1 – 1X Phosphate buffered saline (PBS) 
1X DPBS (Phosphate buffered saline (PBS) GIBCO-Germany 
Calcium chloride (CaCl2 ) GIBCO-Germany 
Magnesium chloride (MgCl2 )  GIBCO-Germany 
 
 
Table 3.2 – Reverse Transcription mix 
Reverse transcription (RT) mix  
1 μl Hexanucleotide Mix (10X) Roche, Germany 
1 μl Deoxynucleotide triphosphate (dNTP) 
mix (10mM) 
Sigma, Germany 
2 μl Dithiothreitol (DTT) mix (10 mM) Invitrogen, Germany 
4 μl 5X RT 1st Strand Buffer Invitrogen, Germany 
1 μl RT enzyme (200 U/ml) Invitrogen, Germany 
ad 20 μl ddH2O Roth, Germany 
 
 
 
Table 3.3 - Quantitative real time-polymerase chain reaction (qRT-PCR)-mix 
Quantitative real time-polymerase chain 
reaction (qRT-PCR)-mix 
 
3 μl Complementary Deoxyribonucleic 
Acid (cDNA) (200ng/µl) 
 
1 μl SYBR Green Master Mix (2x) Applied Biosystems, USA 
2 μl Primer mix (10 pmol/μl) Life Technologies 
10.5 μl ddH2O Roth, Germany 
 
 
 
 
Table 3.4 - 10x (0.125 M) Phosphate buffered saline (PBS), pH 7.3 
10x (0.125 M) Phosphate buffered 
saline (PBS), pH 7.3 
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0.007 M NaH2PO4*H2O Roth, Germany 
0.034 M NaH2PO4*7H2O Roth, Germany 
0.6 M NaCl Roth, Germany 
ad 1 liter ddH2O Roth, Germany 
 
 
 
Tale 3.5 – 2x HBS (Hepes buffered salina) 
2x HBS  
8g NaCl Roth, Germany 
0.38g KCl Roth, Germany 
0.1g Na2HPO4 Roth, Germany 
5g Hepes Roth, Germany 
1g Glucose Roth, Germany 
up to 500 ml ddH2O Roth, Germany 
adjust pH to 7.05   
 
3.1.2  Medium used for culture of cells 
Table 3.6 – Medium type for different cell lines 
Medium type Content  
Freezing Medium 50 %  Fetal bovine serum (FCS) Gibco, Germany 
 40 % cell medium  
 10 % DMSO Sigma, Germany 
MEF Medium  
HEK cells 
DMEM  with  L-glutamine  and  
4.5g/l  D- 
glucose, without sodium pyruvate 
Gibco, Germany 
 0.1 mM NEAA Gibco, Germany 
 1 mM  sodium pyruvate Gibco, Germany 
 2 mM L-glutamine Gibco, Germany 
 10 % FCS Gibco, Germany 
N2 Medium  
ESdM cells 
DMEM/F12 [1:1] with L-
glutamine and  
HEPES [15mM] 
Gibco, Germany 
 1 % N2 supplement Gibco, Germany 
 100 µg/ml penicillin/streptomycin Gibco, Germany 
 
U87 Medium DMEM with high glucose Gibco, Germany 
 10% FCS Gibco, Germany 
 1% penicillin/streptomycin Gibco, Germany 
Results  
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GL261 Medium DMEM/F12 (1:1) with L-
glutamine 
Gibco, Germany 
 1% penicillin/streptomycin Gibco, Germany 
CHO Medium MEMalpha  Gibco, Germany 
 10% FCS Gibco, Germany 
LB medium 10g Tryptone  
5g yeast extract 
10g NaCl 
950 mL deionized water 
Adjust the pH of the medium to 7.0 
using 1N NaOH 
 
Roth, Germany 
Sigma, Germany 
Roth, Germany 
Roth, Germany 
 
3.1.3 Other cell culture reagents 
Table 3.7 – Cell culture reagents 
Reagents  
Opti-MEM Gibco, Germany 
Trypsin-EDTA (0.25%) Gibco, Germany 
Poly-L-lysine Sigma, Germany 
PBS (1X) Gibco, Germany 
Tryptan blue Gibco, Germany 
Isopropanol Sigma, Germany 
Fluoresbrite polychromatic red 1.0 micron 
microspheres (the beads for phagocytosis assay) 
Polyscience, USA 
Neuraminidase (sialidase) Roche, Germany 
Magnesium II Chloride (MgCl2) Sigma, Germany 
Manganese II Chloride (MnCl2) Sigma, Germany 
Bovine serum albumin (BSA) Sigma, Germany 
Ethanol Roth, Germany 
Hexanucleotide Mix (10x) Roche, Germany 
Puromycin PAA, Germany 
RNeasy Mini Kit Qiagen, Germany 
RNAse free DNAse Kit Qiagen, Germany 
SuperScript® III Platinum® Two-Step qRT-
PCR Kit 
Invitrogen, Germany 
HiPure Plasmid Filter Purification Kits Invitrogen, Germany 
Lipofectamine Invitrogen, Germany 
Propidium iodide Sigma, Germany 
Trypsin  Gibco, Germany 
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3.1.4 Glycosaminoglycan Reagents 
Table 3.8 – Glycosaminoglycans reagents  
Components  Company  
Disaccharides (from CS-A derived – 
DS-4S) 
Sigma, Germany 
Chondroitin sulfate sodium salt from 
shark cartilage 
Sigma, Germany 
Chondroitin sulfate sodium salt A 
from bovine cartilage 
Sigma,Germany 
Chondroitin sulfate sodium salt C 
from shark cartilage 
Nacalai tesque, Germany 
Adequan IM – polysulfated 
Glycosaminoglycan 500mg/5mL 
Novartis 
Dextran sulfate from Leuconostoc. Sigma, Germany 
Chondroitinase ABC Seikagaku, Germany 
Chondroitin disaccharide not 
sulfated (DS-0S) 
Sigma, Germany 
Chondroitin disaccharide sulfated 
position 4S (DS-4S) 
Sigma, Germany 
 
3.1.5 Vectors 
Table 3.9 – Packing plasmids 
Packaging Plasmids  
Packaging plasmid PLP1 ViraPower ™ Invitrogen, UK 
Packaging plasmid PLP2 ViraPower Invitrogen, UK 
Packaging plasmid PLP3 ViraPower ™ Invitrogen, UK 
 
 
Table 3. 1.1 - shRNA Plasmids used for knockdown of TREM2 in ESdM cell line 
Clone1:TRCN0000179471 Mouse NM_026192.1-1754s1c1 (Plasmids1) 
Vector pLKO_TRC005 
Species Mus musculus 
Sequencing Primers 
Forward 
5'CCGGGCCTTCTTCTCTTGTTGTCATCTCGAG 
ATGACAACAAGAGAAGAAGGCTTTTTG-3' 
Sequencing Primers 
Reverse 
5'AATTCAAAAAGCCTTCTTCTCTTGTTGTCAT 
CTCGAGATGACAACAAGAGAAGAAGGC-3' 
Hairpin sequence 5'CCCGGGCCTTCTTCTCTTGTTGTCATCTCGA 
GATGACAACAAGAGAAGAAGGC-TTTTTTG-3' 
Antibiotic Ampicilin 
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Clone2:TRCN0000184478 Mouse NM_026192.1-897s1c1 (Plasmids2) 
Vector pLKO_TRC005 
Species Mus musculus 
Sequencing Primers 
Forward 
5'CCGGGCTGAATTACAAACGGTCCGACTCGAG 
TCGGACCGTTTGTAATTCAGCTTTTTG-3' 
Sequencing Primers 
Reverse 
5'AATTCAAAAAGCTGAATTACAAACGGTCCGA 
CTCGAGTCGGACCGTTTGTAATTCAGC-3' 
Hairpin sequence 5'CCCGGGCTGAATTACAAACGGTCCGACTCGA 
GTCGGACCGTTTGTAATTCAGC-TTTTTTG-3' 
Antibiotic Ampicillin 
 
 
Clone3: TRCN0000244544 Mouse NM_026192.2-2405s21c1 (Plasmids3) 
Vector pLKO_TRC005 
Species Mus musculus 
Sequencing Primers 
Forward 
5'CCGGCCTTGCGGGAATAGAATTATTCTCGA 
GAATAATTCTATTCCCGCAAGGTTTTTG-3' 
Sequencing Primers 
Reverse 
5'AATTCAAAAACCTTGCGGGAATAGAATTAT 
TCTCGAGAATAATTCTATTCCCGCAAGG-3' 
Hairpin sequence 5'CCGGCCTTGCGGGAATAGAATTATTCTCGA 
GAATAATTCTATTCCCGCAAGG-TTTTTG-3' 
Antibiotic Ampicillin 
 
3.1.6 Proteins and Antibodies 
Table 3.1.2 – Fusion Proteins for flow cytometry 
Proteins Species Reactivity Dilution Company 
TREM2 - Fc fusion protein Mouse 25ug R&D, Germany 
Siglec F – Fc fusion protein Mouse 25ug R&D, Germany 
 
 
Table 3.1.3 – Primary and Isotype antibody for flow cytometry 
Antibody Species Reactivity Dilution Company 
TREM2 Mouse 1:100 R&D, Germany 
Isotype IgG1 Rat 1:100 BD Biosciences, 
Germany 
 
 
Table 3.1.4 – Secondary antibody for fusion protein 
Protein Host Directed 
Against 
Dilution Company 
Fluorescein FITC Goat Mouse Fc 
gamma 
10µg Jackson ImmunoResearch, USA 
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Table 3.1.5 – Secondary antibody for flow cytometry 
Antibody Host Directed 
Against 
Dilution Company 
PE Goat Mouse 1:100 Jackson ImmunoResearch, USA 
 
3.1.7 Primers used for qRT-PCR 
Oligonucleotides were obtained from Life Technologies.  
 
Table 3.1.6 – Primers used for qRT-PCR 
Name Forward Sequence Reverse Sequence 
TREM2 5’TGCAAGGTCCCCTCCGGC3’ 5’GGGCTTGGGACAGGGCTGTGA3’ 
IL-1ß 5’CTTCCTTGTGCAAGTGTCTG3‘ 5’CAGGTCATTCTCATCACTGTC3‘ 
iNOS 5’AAGCCCCGCTACTACTCCAT3‘ 5’GCTTCAGGTTCCTGATCCAA3‘ 
TNF-α 5’TGATCCGCGACGTGGAA3‘ 5’ACCGCCTGGAGTTCTGGAA3‘ 
GAPDH 5’ACAACTTTGGCATTGTGGAA3‘ 5’GATGCAGGGATGATGTTCTG3‘ 
 
3.1.8 Cells lines 
Table 3.1.7 – Different cells lines 
Cells Type  Received From 
ESdM cell line ESdM cells were already established using a protocol for 
microglia precursor cell line differentiation from murine 
embryonic stem cells was established by group of Prof. 
Harald Neumann (Napoli et al., 2009). 
U87 cells MG Human glioblastoma-astrocytoma cells (abcam). 
CHO cells Chinese hamster ovarien cells (Life technologies). 
HEK cells 293FT Human Embryonic Kidney 293 cells (Life technologies). 
GL261 Mouse glioma cell line (Hertie-Institute for clinical 
neurology, Germany) 
SMA560-MS Small-cell  lung carcinoma (Hertie-Institute for clinical 
neurology, Germany) 
Competent cells DHαE
TM   
cells (Invitrogen) 
ESdM - DAP12 cells ESdM cells were already established using a protocol for 
microglia precursor cell line differentiation from murine 
embryonic stem cells was established by group of Prof. 
Harald Neumann, but that cells was also performed by Dr. 
Liviu Bodea  (Napoli et al., 2009). 
ESdM DAP12 Full 
Length  
DAP12 Full Length ITAM signalling overexpressed. 
ESdM DAP12 
Truncated  
 ITAM signaling motifs deleted. 
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ESdM GFP Control vectors were inserted in lentiviral expression 
plasmids containing an internal ribosome entry site (IRES) 
enhanced green fluorescence protein (eGFP). 
 
 
3.1.8 Consumables Material  
 
Material Company 
Aluminium folie Carl Roth GmbH &  Co  KG,  Karlsruhe, Germany 
Cell strainer BD Biosciences, NJ,USA 
Corning cell scraper   Sigma Aldrich Chemie GmbH, Steinheim, Germany 
Cryovials [2 ml] Nunc GmbH & Co KG, Wiesbaden, Germany 
Falcon tubes [15 ml] Cellstar, Greiner Bio One, Frickenhausen, Germany 
Falcon tubes [50 ml]  Sarstedt Ag & CoKG, N.rnbrecht, Germany 
Filtropur [0.25 μm, 0.4 μm] Sarstedt Ag & CoKG, N.rnbrecht, Germany 
Graduate pipette Tips  
[10 μl,100 μl, 1000 μl] 
Starlab GmbH, Ahrensburg, Germany 
Lab-Tek Chamber Slide 
w/Cover 
Thermo Scientific, USA 
Latex gloves   Ansell Healthcare Europe NV, Brussels, Belgium 
Microscope cover glasses P.  Marienfeld  GmbH,  Lauda-K.nigshofen, Germany 
Nitrile gloves Ansell Healthcare Europe NV, Brussels 
Parafilm Bemis Flexible Packaging, WI, USA 
Pasteur pipettes Brand GmbH & Co KG, Wertheim, Germany 
Petri dishes Sarstedt AG  & Co  KG, Nurnbrecht, Germany 
Pipettes [5 ml, 10 ml, 25 ml] Sarstedt AG  & Co  KG, Nurnbrecht, Germany 
Safe-seal micro tubes [0.5 
ml,1.5 ml, 2 ml] 
Sarstedt AG  & Co  KG, Nurnbrecht, Germany 
Syringes BD Biosciences, NJ,USA 
Tissue culture dishes TPP, Switzerland 
Vacuum driven disposable 
bottle top filter 
Millipore Corporation, Bitterica, MA, USA 
0.45 μm pore size filter stericup (Millipore, USA) 
10 μl, 100 μl, 1000 μl pipette 
tips 
(Eppendorf, Germany) 
15 and 10 cm2 tissue cell 
culture flask 
(Sarstedt, Germany) 
6-well-plate (Cellstar, Germany) 
5, 10 and 25 ml disposable 
plastic pipette 
(Costar, Germany) 
FACs tube 5mL  12mm (Sarstedt, Germany) 
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PCR tubes (Biozym Diagnostics, Germany) 
Cell scraper (Sarstedt, Germany) 
 
3.1.10 Equipment 
 
EQUIPMENT  
- 20 °C freezer   Liebherr, Bulle, Switzerland 
+ 4 °C fridge   Liebherr, Bulle, Switzerland 
Apotome Carl Zeiss AG, Jena, Germany    
BD FacsCalibur BD Biosciences, NJ,USA 
Cell Mate II [pipette boy] Thermo Fisher Scientific Inc, NH, USA 
Eppendorf Mastercycler epgradient   Eppendorf AG, Hamburg, Germany 
Hera cell 150 [incubator] Heraeus Holding GmbH, Hanau, Germany 
Hera freeze [- 80.C freezer] Heraeus Holding GmbH, Hanau, Germany 
Hera safe [laminar-air flow workbench] Kendro Laboratory Products GmbH, 
Langenselbold, Germany 
Megafuge1.0R [centrifuge] Heraeus Holding GmbH, Hanau, Germany 
Nanodrop 1000 Spectrophotometer PeqLab Biotechnologie GMBH Erlangen, 
Germany 
Pipettes [10μl, 100μl, 1000μl]   Eppendorf AG, Hamburg, Germany 
Systec D-150 [autoclave]   Systec GmbH, Wettenberg, Germany 
Thermomixer compact   Eppendorf AG, Hamburg, Germany 
Water bath WB/OB7-45 Memmert G 
Real time thermocycler ABI Prism 5700 
Seqeunce Detection System, 
Applied Biosystems, UK 
Vortex 2X2 (VelpScientifica, Germany) 
Centrifuges Sorvall Discovery 90SE,  
Megafuge, Biofuge Fresco 
(Hitachi, Germany), (1.OR. Heraeus, 
Germany), (Heraeus, Germany) 
 
 
3.1.11 Kits 
 
KIT Company 
HiPure plasmid filter DNA purification kit Life Technologies™ 
MiniElute PCR Purification Kit Qiagen, Germany 
QIAquick Gel Extraction Kit Qiagen, Germany 
QIAprep Spin Miniprep Kit Qiagen, Germany 
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Rneasy® Mini Kit Qiagen, Germany 
 
3.1.12 Software/Databases 
 
Software Producer 
AxioVision SE64, Rel 4.9.1 Carl Zeiss AG, Jena, Germany    
Cellquest Pro BD Biosciences, NJ,USA 
CorelDRAW Graphics Suite x5 Corel, Germany 
FlowJo 6.4.7 Tree Star, USA 
Gene Designer 2.0 DNA2.0, Inc. USA 
Geneious 6.1.6 Biomatters Ltd, New Zealand 
Mendeley Mendeley Ltd, USA 
Microsoft Office 2010 Microsoft, USA 
 
3.2 Methods:  
3.2.1 Flow cytometry analysis of microglia line 
Mouse microglial line (ESdM – embryonic stem cell derived microglial precursor cells) cells 
were collected using a cell scraper or trypsin. Cells were stained with TREM2 antibody (table 
3.1.3 for 60 minutes (min) on ice. After washing with PBS, samples were incubated with a 
corresponding secondary antibody for 30 min on ice in darkness (table 3.1.5). Corresponding 
isotype control antibody (table 3.1.3) and non-stained cells were used as negative controls. 
Analysis was performed with a FACS calibur flow cytometer and FlowJo Software.     
3.2.2 Maxiprep 
The E. coli competent cells (Invitrogen) were thawn on ice for 15 min and 1µg if each DNA 
plasmids for TREM2 knockdown (see above table 3.1.1) were added to competent cells and 
mixed. After incubation for 30 min on ice, cells were heat shocked for 45 seconds in a water 
bath at 42°C, and then transferred back on ice. 900 µL of LB medium were added, mixed and 
transferred to culture tubes and were shaken for 1 hour in 37 °C at 250 rpm. After spining 
down, the bacteria were resuspended in 100 µl of LB medium and distributed on a plate with 
specific antibiotics. Then, the bacteria were incubated overnight at 37ºC. One single colony 
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was used for high-copy number of plasmids and incubated with 250 ml LB medium with 
respective antibiotics of plasmids and incubated overnight at 37ºC. Then, the purification of 
DNA plasmid was performed by HiPure Plasmid Filter Purification Kits (Invitrogen, K2100-
27). 
3.2.3 RT-PCR and RNA Isolation  
Cells were homogenized in 350 µl of ß-mercaptoethanol and 70 % ethanol. Subsequently, 
RNA was isolated either using the RNeasy® mini Kit, following manufacturer’s 
specifications. The RNA content was measured using a Nanodrop spectrophotometer. For 
cDNA production 50 µg total RNA was reverse transcribed using SuperScript III reverse 
transcriptase and hexameric random primers (table 3.1.8).  
For the evaluation of transcriptional levels of cytokines and expression of TREM2 receptor in 
microglial cell line, Real Time - PCR was performed using 600 ng of cDNA, SYBR GreenER 
qPCRSuperMix Universal and 400 nM mouse primers (table 3.1.6) into a final reaction 
volume of 25 µL.  
For amplifications (table 3.1.9), a Mastercycler epgradient S® was used and the results were 
evaluated with the manufacturer’s software. Amplification specificity was confirmed by 
melting curve analysis of GAPDH and the quantification was carried out using the ΔΔCt  
method.  
Table 3.1.8 – Reverse transcription 
Prepare RT Mix (I) Component Amount Manufacturer Registered 
office  
 RNA 11 µL 
(50 µg)  
  
 Hexanucleotids (mM)  1 µL Roche Grenzach-
Wyhlen, DE 
 dNTPs (mM each) 1 µL Paqlab Erlangen, DE  
 Start RT 
Program 
Temperature Time    
 65°C 5 min    
 4°C 1 min   
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 4°C pause   
Add RT Mix (II) Component Amount Manufacturer Registered 
office 
 Forwards Strand  
Buffer 5x  
4 µL Invitrogen, 
LifeTechnolgies 
GmbH  
Darmstadt, 
DE 
 DTT (0.1 M) 2 µL Invitrogen,  
LifeTechnolgies  
GmbH  
Darmstadt, 
DE 
 SuperScript III 1 µL Invitrogen,  
LifeTechnolgies  
GmbH  
Darmstadt, 
DE 
 Continue RT 
Program 
Temperature Time   
 25°C 5 min   
 55°C 1h    
 70°C 15 min   
 4°C ∞   
 
 
 
Table 3.1.9 – RT-PCR Program 
Step Temperature Time Cycles  
1. Initial denaturation 95°C 10 min   
2. Denaturation 95°C 15 s  40x  
3. Annealing 60°C 30s  40x  
4. Elongation 72°C 30s  40x  
5. Inactivation 95°C 10 min  
6. Melting curve 60°C-95°C 20 min   
7. Final 95°C 15 s   
8. Store 4°C ∞  
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3.2.1 Viral particle production and lentiviral transfection of TREM2 knockdown 
The 293FT-HEK cells were kept in Dulbecco's Modified Eagle's Medium (DMEM; Gibco) 
with 1% penicillin/streptomycin and 4 mM glucose at 37°C. Viral particles were produced in 
15 cm dishes precoated with poly-L-Lysine. 25 μg of targeting plasmid together with each of 
the three packaging helper plasmids were co-transfected using Lipofectamine to 6.5 million 
293FT-HEK cells and incubated for 20-25 minutes at room temperature (table 3.2.1). Cells 
were transfected in Trans-MEF-medium (MEF medium without antibiotics containing 5% 
FCS). Medium was replaced at 6 - 16 hours post-transfection. Viral supernatant (10 ml) was 
collected at 48 - 72 hours post-transfection. Viral particles were then centrifuged using a 
Megafuge (Heraeus, Germany, 1300 rpm) for 3 min at 4°C. The viral particle pellet was 
resuspended in 5 ml MEF medium. Viral particles were either immediately applied to 
transduce cells or stored at -80°C. Cells having been incubated with lentiviral plasmids to 
knock-down TREM2 were analyzed by RT-PCR to confirm the knock-down of TREM2 gene 
transcripts. 
Table 3.2.1 – Lentivirus generation (quantities per 15 cm2 dish) 
Step Component Amount 
Plasmid Mix Plasmid of interest 25 µg 
 pLP1 (pMDL gag/pol RRE) 25 µg 
 pLP2 (pRSV-Rev) 12.5 µg  
 pLP3 15 µg  
 Lipofectamine 90 µl 
 Medium 7 ml 
 
3.2.2 Phagocytosis assay 
For analysis of phagocytosis; 100,000 cells were seeded to each well of a 6-well-plate in N2 medium. 
At the second day, cells were incubated with different concentrations of CS-A or with dissacharides 
(DS-4S). After 2 hours of incubation with CS-A or 1 hour with sulfated DS(4S) and non-sulfated 
DS(0S). Then, those cells were labeled with microsphere beads (fluoresbrite Polycromatic Red 
microspheres 1.0um, Polyscience, 18660). Afterwards, 2.5 μl/2 mL microsphere beads were added to 
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each well for 30 minutes, washed with PBS and analyzed by FACS calibur TM flow cytometer (BD 
Biosciences).  
3.2.1 Chondroitinase ABC activity assay 
The chondroitinase ABC (ChABC) was used (Seikagu Biobusiness – 100330); where U87 
cells (1 million) were pretreated with 50, 100 and 250 mU/ml of ChABC and then incubated 
for 1 or 24 hours at 37°C. ChABC removes the family of chondroitin sulfates from the 
glycocalyx of glioma cells. Afterwards U87 cells were washed twice with PBS and incubated 
with a TREM2b-Fc fusion protein for 60 minutes and after with a FITC-conjugated secondary 
antibody directed against the Fc part of TREM2b-Fc fusion protein for 30 minutes at 4 °C. 
Cells were washed twice in PBS and resuspended in 500 µl PBS. Live gating was performed 
by adding propridium iodide. Analysis was done with a FACS calibur flow cytometer (BD 
Biosciences).  
3.2.2 Removal of sialic acid by Neuraminidase treatment 
The U87 cells were treated with neuraminidase (Roche, Germany), an enzyme that can cleave and 
remove the sialic acids from the glycocalyx of glioma cells. The enzyme was added to the medium at a 
concentration of 2.5 mU/ml. Cells were incubated at 37 ºC for 2 hours. The cells were collected and 
incubated with Siglec F-Fc fusion protein or with TREM2b-Fc fusion protein protein for 1 hour at 4 
ºC. Siglec F can recognize the sialic-containing Lewis-X glycosides residues. Results were analyzed 
with a FACS calibur flow cytometer (BD Biosciences) and FlowJo software. 
3.2.3 Binding of TREM2b-Fc fusion protein or Siglec F-Fc fusion protein with 
polysaccharides  U87 cells and FACS analysis 
Cells were collected by a cell scraper, centrifuged and the pellet was resuspended in 500 µl of 
U87 medium without FCS and incubated with the 8 µg of TREM2b Fc chimera or Siglec F Fc 
chimera for 1 hour at 4 °C. For blocking of the TREM2 binding, polysaccharides were added 
to the incubation step with the Fc chimera at different concentrations of chondroitin sulfate 
sodium salt from shark cartilage (Sigma – C4384); chondroitin sulfate A sodium salt from 
bovine trachea (Sigma – C9819); dextran sulfate sodium salt from Leuconostoc ssp.; Adequan 
canine (Polysulfated Glycosaminoglycan – Novartis Animal Health) (table 3.8). Afterwards, 
cells were washed twice with PBS and incubated in a FITC-conjugated secondary antibody 
directed against the Fc part for 30 minutes at 4 °C. Cells were washed twice in PBS and 
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resuspended in 500 µl PBS. Live gating was performed by adding propidium iodide. Analysis 
was done with a FACS calibur TM flow cytometer (BD Biosciences).  
3.2.4 Binding of TREM2b-Fc fusion protein or Siglec F-Fc fusion protein to mouse or 
human glioblastoma cells 
Cells were collected and the cell pellet was resuspended in 500 µl of U87 cells medium and 
incubated with the 8 µg of TREM2b Fc chimera or Siglec F - Fc chimera for 1 hour at 4 °C. 
Afterwards, cells were washed twice with PBS and incubated in a FITC-conjugated secondary 
antibody directed against the Fc part for 30 minutes at 4 °C. Cells were washed twice in PBS 
and resuspended in 500 µl PBS. Live gating was performed by adding propidium iodide 
Analysis was done with a FACS calibur TM flow cytometer (BD Biosciences). 
3.2.5 Analysis of pro- and anti- inflammatory cytokine gene transcripts by real-time 
PCR 
RNA was isolated with the RNeasy Mini Kit from ESdM cells after stimulation with 2 mM of 
CS-A or 0.2 mM of DS-4S, 0.2 mM of DS-0S for either 30 minutes, 1 or 2 hours. And the 
preparation of cDNA, trancriptase reverse and qRT-PCR were already described in tables 
3.1.8 and 3.1.9.  
   3.2.6 Statistical analysis 
 
Statistical analyses were performed using Graph Pad Prism 5 Software. For two groups, 
students t-test was used, for data with more than two groups, analysis of variance (ANOVA) 
followed by Bonferroni test was used. Data are presented as mean +/- SEM of at least three 
independent experiments. 
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4. Results: 
4.1 Binding of TREM2-Fc fusion protein to the cell surface 
Recently, it was shown that apoptotic neural cell membrane contain components that can bind 
to and stimulate TREM2 receptor of microglia (Hsieh et al., 2009). Here, it was also shown 
that TREM2 can bind to CHO and U87 cells. To confirm the binding of TREM2 to different 
cell lines, purified mouse TREM2b-Fc-fusion protein and positive control Siglec F-Fc fusion 
protein were incubated with GL261, SMA-560, CHO and U87 cells using flow cytometry. 
The U87 cells are a human primary glioblastoma cell line was obtained from a stage four 44 
year-old cancer patient (Clark et al.), the GL261 cells are mouse glioma 261 (Gl261) cells are 
used frequently in experimental glioblastoma therapy (Szatmari et al., 2006),  SMA-560 cells 
are Small-cell carcinoma also known as small-cell lung cancer is a type of highly malignant 
cancer that most commonly arises within the lung (Nasu et al.) and CHO cells are a cell line 
derived from the ovary of the Chinese hamster. 
The Siglec F-Fc fusion protein was used as a positive control because Siglec F is also a 
microglia cell surface receptor which can recognize sialic acid that are express on altered 
glycocalyx of glioma or CHO cells and is a monosaccharide with a nine carbon backbone, 
they occur at the end of sugar chains connected to the surfaces of cells with soluble 
glycoproteins and glycolipids. The binding of mouse TREM2b-Fc fusion protein or Siglec F-
Fc fusion protein to glioma and CHO cells were detected by flow cytometry (Figure 4.1). The 
results shown the TREM2b – Fc fusion protein and Siglec F – Fc fusion protein can binds to 
glioma and CHO cells and this binding of TREM2b – Fc fusion protein to glioma and CHO 
cells are lower fluorescence intensity when compared to positive control Siglec F- Fc fusion 
protein (Figure 4.1 a, b, c and d).  
 It was shown that the TREM2b - Fc fusion protein is capable of binding to SMA-560 cells 
(60.2 ± 4.6 fluorescence units, p<0.001), to CHO cells (48.7 ± 5.9 fluorescence units, 
p<0.001) and to GL261 cells (203 ± 2.7 fluorescence units, p>0.05), but with lower capacity 
when compared to U87 cells (310 ± 34.9 fluorescence units, p<0.001) (Figure 4.1 e). The 
positive control Siglec F – Fc fusion protein bound to CHO cells (124 ± 14.4 fluorescence 
units, p<0.001), to SMA-560 cells (250 ± 8.9 fluorescence units, p>0.05), to GL261 cells (306 
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± 6.8 fluorescence units, p>0.05) and to U87 cells (405 ± 3.7 fluorescence units, p<0.001) 
(Figure 4.1 f). 
In summary, these results showed that the mouse TREM2 receptor can bind and recognize 
structures which are expressed on alter glycocalyx of glioma or CHO cells. In addition, the 
Siglec F receptor can recognize the sialic acids which are expressed on glycocalyx of glioma 
or CHO cells. 
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Figure 4.1 - TREM2b-Fc-fusion protein or Siglec F-Fc-fusion protein binding to U87, 
GL261, SMA-560, and CHO cells. Binding of mouse Siglec F-Fc (red) and TREM2b-Fc-
fusion protein (blue) to (a) U87 cells, (b) GL261 cells, (c) SMA MS cells, and (d) CHO cells. 
Negative control (grey) - secondary antibody. (e and f) Representative images out of three 
independent experiments. (e) TREM2b-Fc-fusion protein binds to U87, GL261, SMA MS and 
CHO cells or (f) Siglec F-Fc-fusion protein binds to U87, GL261, SMA MS and CHO cell. Data 
are presented as mean±SEM, ANOVA – Bonferroni’s multiple comparisons using post-hoc test: 
***p< 0.001. 
4.2 Removing of chondroitin sulfate groups of the glycocalyx of glioblastoma cells by 
chondroitinase ABC changed the binding of TREM2 to glioma cells 
Bacterial ChABC was used to remove the chondroitin sulfate chains from to the glycocalyx of 
glioblastoma cells. 
To test whether the pretreatment of U87 cells with ChABC can change the binding of mouse 
TREM2-Fc fusion protein to U87 cells, these cells received a pre-treatment with 100 mU/ml 
of ChABC for 24 hours at 37°C. U87 cells were used because, as shown before, they can 
increase the binding of TREM2-Fc fusion protein or Siglec F- fusion protein compared to 
other cell types. The Activity of Chondroitinase ABC of glioma cells can be seen in Figure 4.2 a. 
U87 cells were treated with 100 mU/ml of ChABC, partial inhibition of the binding of 
TREM2b-Fc fusion protein was seen when compared to untreated cells (Figure 4.2 b). But, 
when U87 cells were treated with 100 mU/ml of ChABC and were incubated with the positive 
control Siglec F-Fc fusion protein, no change in the binding of Siglec F was seen was seen 
(Figure 4.2 c). This proves that the TREM2 receptor can specifically recognize chondroitin 
sulfate groups altered. 
Here we see that binding of TREM2b-Fc-fusion protein to the glioma cells is significantly 
reduced after the removal of chondroitin sulfate groups from the glycocalyx of the U87 cells 
(45.1 ± 2.4 fluorescence units, p<0.001) treatment when compared with untreated cells (310 ± 
7.1 fluorescence units, p<0.001) (Figure 4.2 d). On the other hand, when the glioma cells were 
treated with ChABC and incubated with the mouse Siglec F-Fc-fusion protein, the results 
showed no significant change in the binding capacity of Siglec F-Fc-fusion protein (405.3 ± 
4.3 fluorescence units, p>0.05) when compared with cells receiving no treatment (405.4 ± 4.4 
fluorescence units, p>0.05) (figure 4.2 e).  
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The treatment of glioma cells with ChABC reduces the binding of mouse TREM2b-Fc-fusion 
protein to U87 cells, but does not change the binding of Siglec F-Fc fusion protein to U87 
cells. 
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Figure 4.2 –  Pretreatment of U87 cells with Chondroitinase ABC after 24 hours (a) Activity of 
Chondroitinase ABC. Chondroitinase ABC from Proteus vulgaris catalyzes the degradation of CS-A, 
CS-C, CS and dermatan sulfate mainly into disaccharides. (b) Binding of TREM2b-Fc-fusion protein 
(blue) is partially inhibited after incubation with 100 mU/ml of ChABC for 24 hours (green). (c) 
Binding of Siglec F-Fc-fusion protein (red) is not changed after incubation with 100 mU/mL of 
ChABC for 24 hours (black). (d and e) Graphics represent mean±SEM of fluorescence intensity of 
three different experiments of ChABC pretreated U87 cells. Secondary antibody control – grey. Data 
are presented as ANOVA - Bonferroni’s multiple comparasions using post-hoc test: ***p<0.001 
and NS: Not significant. 
4.3 TREM2 is not dependent on removal of sialic acids  from the glycocalyx of glioma 
cells 
 U87 cells were pretreated with 25 mU/ml sialidase for 2.5 hours at 37°C. Sialidase is a 
enzyme can hydrolyse alpha-(2->3)-, alpha-(2->6)-, alpha-(2->8)-glycosidic linkages of 
terminal sialic residues in oligosaccharides, glycoproteins, glycolipids, colominic acid and 
synthetic substrates (Luo et al., 1998). That experiment was performed to prove that the 
TREM2 can binds specific in chondroitin sulfate group are expressed in glycocalyx of glioma 
cell and not in other structures. The activity of sialidase enzyme on glycocalyx of glioma cells 
is shown in Figure 4.3 a. Flow cytometry shows that pretreatment of U87 cells with sialidase 
reduces the binding of Siglec F-Fc-fusion protein to U87 cells (Figure 4.3 b). On the other 
hand, sialidase pretreatment of U87 cells does not change the binding of TREM2b-Fc fusion 
protein to glioma cells (Figure 4.3 c).   
The results are given as mean ± SEM of fluorescence intensity of three independent 
experiments. The pretreatment of glioma cells with sialidase showed significant reduction of 
the binding of Siglec F-Fusion protein to U87 cells (29.7 ± 9.6 fluorescence units, p<0.001) 
when compared with untreated cells (254 ± 11 fluorescence units, p<0.001) (Figure 4.3 d). 
Interestingly, the glioma cells which were pretreated with sialidase and then incubated with 
TREM2b-Fc fusion protein showed no significant change the binding of TREM2b-Fc fusion 
protein to glioma cells (83 ± 9.6 fluorescence units, p>0.05) when compared to untreated cells 
(84 ± 9.7 fluorescence units, p>0.05) (Figure 4.3 e).  
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Figure 4.3 – Removal of sialic acids from the glycocalyx of U87 cells does not change the binding 
of TREM2 to glioma cells.   (a) Activity of sialidase enzyme. Sialidase hydrolyses alpha-2,3-, alpha-
2,6-, and alpha-2,8-glycosidic linkages of terminal sialic acid residues. (b) ) Binding of TREM2b-Fc-
fusion protein to U87 cells (blue) did not change after pretreatment with 25 mU/ml of sialidase 
(green). (c) Binding of Siglec F-Fc-fusion protein to U87 cells (red) is nearly completely inhibited 
after incubation with 25 mU/ml of sialidase (black). (d) Graphic represent mean±SEM of fluorescence 
intensities of three different experiments of Siglec-F-Fc (d) or TREM2b-Fc fusion protein (e) binding 
after removal of sialic acids. Negative control is secondary antibody (grey). Data are presented as 
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ANOVA - Bonferroni’s multiple multiple comparasions using post-hoc test ***p<0.001 and NS: 
not significant. 
4.4 Chondroitin sulfate and dextran sulfate inhibit the interaction of TREM2b-Fc-
fusion proteins with glioma cells 
To test possible ligands as binding partners for TREM2, TREM2b-Fc-fusion protein was 
incubated with different glycosaminoglycans. The following glycosaminoglycans were tested: 
1) Dextran sulfate (DXS),   
2) Chondroitin polysulfate (Adequan), 
3) Chondroitin sulfate A (chondroitin-4-sulfate), 
4) Chondroitin sulfate C (chondroitin-6-sulfate), 
5) Chondroitin sulfate (CS; have every sulfate  group of CS: CS-A, CS-B, CS-C, CS-
D and CS-E), 
 
Table 4.1 – Mean±SEM, mean of of fluorescence intensity for inhibition of TREM2bFc-fusion protein 
binding to glioma cells. In absence of glycosaminoglycans the mean value of the binding of TREM2b-
Fc fusion protein for every group is 310 ± 34.9. 
 
Glycosaminoglycan Concentration  
(mM) 
Fluorescence Intensity  (Mean  ± 
SEM ) 
Dextran sulfate   
 0.2 mM 30.7 ± 6.4 
 0.4 mM 31.2 ± 6.0 
 1 mM 31.5 ± 5.0 
 2 mM 32.3 ± 5.1 
 4 mM 31.7  ± 9.0 
   
Chondroitin sulfate   
 4 mM 79  ± 5.1 
 8 mM 80.3  ± 2.6 
 20 mM 78.8  ± 7.5 
   
Chondroitin sulfate A   
 0.2 mM 49.3  ± 4.7 
 0.5 mM 48.5  ± 1.2 
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 2 mM 52  ± 6.1 
 10 mM 45  ± 3.2 
Chondroitin sulfate C   
 0.1 mM 303  ± 8.6 
 0.2 mM 327  ± 7.5 
 0.4 mM 299  ± 5.2 
 2 mM 342  ± 8.3 
 4 mM 315  ± 7.7 
Chondroitin polysulfate 
Adequan 
  
 0.3 mM 3.5  ± 8.7 
 0.6 mM 4.4  ± 10.9 
 1.6 mM 5.8  ± 4.2 
 3 mM 13.6  ± 6.2 
 6 mM 2.9  ± 7.1 
 16 mM 3.8  ± 9.3 
 30 mM 8.0  ± 19.7 
 60 mM 8.0  ± 19.7 
 130 mM 2.7  ± 4.3 
 150 mM 2.4  ± 6.0 
  200 mM 3.3  ± 8.2 
 300 mM 2.9  ± 7.1 
 
Synthetic glycosaminoglycans were tested by flow cytometry (Table 4.1). Results showed that 
the binding of TREM2b-Fc fusion protein to glioma cells changes after incubation with 
different glycosaminoglycans when compared to the controls. Binding of TREM2b-Fc fusion 
protein to glioma cells reduces after incubation with 2 mM of dextran sulfate (Figure 4.4 a), 3 
mM of adequan (Figure 4.4 b), 8 mM of CS (Figure 4.4 c), 2 mM of CS-A (Figure 4.4 d). 
Different concentrations of CS-C cannot change the binding of TREM2b-Fc fusion protein to 
glioma cells (Figure 4.4 e).  
To confirm that the TREM2b-Fc fusion protein cannot bind to other structures which are 
expressed on glycocalyx of glioma cells, positive control Siglec F-Fc fusion protein was used 
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and also incubated with 2 mM of CS-A.  The results showed that CS-A cannot change the 
binding of Siglec Fc fusion protein to glioma cells when compared with untreated cells. That 
proves the TREM2 can bind and recognize specific CS group and not other components 
(Figure 4.4 f). 
Thus, the binding of TREM2b-Fc-fusion protein to the glioma cells is mostly inhibited after 
incubation of cells with 2 mM of dextran sulfate 32.3 ± 5.1 when compared with untreated 
cells (control – just incubated with TREM2b-Fc fusion protein), (85.6 ± 2.5 fluorescence 
units, p<0.001). Adequan, a polysulfated glycosaminoglycan which is chemically similar to 
natural mucopolysaccharides found in cartilaginous tissues, was studied at different 
concentrations. The results show that the binding of the TREM2-Fc-fusion protein to U87 
cells is completely inhibited with 3 mM adequan (13.6  ± 6.3 fluorescence intensity, p<0.001), 
(Figure 4.4 g).  
The additionally, the biological substance CS was tested to demonstrate that binding of the 
TREM2b-Fc fusion protein to U87 cells can be inhibited at different levels of chondroitin 
sulfate (CS – contains  every chondroitin sulfate group). The results show that binding of 
TREM2-Fc-fusion protein to U87 cells can be significantly partially inhibited after incubation 
with 8 mM of chondroitin sulfate (80.3 ± 2.6 fluorescence units, p>0.05) (Figure 4.4 g). 
To confirm that the TREM2 can bind and recognize specific chondroitin sulfate groups and 
not other structures, Siglec F-fc fusion protein was used as a positive control. The results 
showed that when the Siglec F-Fc fusion protein was incubated with 2 mM chondroitin sulfate 
A (150 ± 2.6 fluorescence units, p>0.05) cannot inhibited the Siglec F-fc fusion protein 
binding to glioma cells (Figure 4.4 h) when compared with untreated cells (149 ± 2.5 
fluorescence units, p>0.05). Together, these results show that the microglial TREM2 can bind 
to members of glycosaminoglycas such as chondroitin sulfate, which partialy inhibits the 
binding to glioma cells after incubation of cells with 2 mM chondroitin sulfate A.  
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Figure 4.4 - Interaction between TREM2b-Fc-fusion protein and different polysaccharides. (a)  
Binding of TREM2b-Fc-fusion protein to U87 cells (blue) is partially inhibited after incubation with 2 
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mM of dextran sulfate (DXS; green). (b) Adequan 3mM (green) binds to TREM2b-Fc-fusion protein 
and can completely inhibit the binding to U87 cells. (c) Binding of TREM2b-Fc-fusion protein to U87 
cells (blue) is partially inhibited with 8 mM of chondroitin sulfate (CS, green). (d) Binding of 
TREM2b-Fc-fusion protein to U87 cells (blue) is partially inhibited with 2 mM  chondroitin sulfate A 
(CS-A, green). (e) Binding of TREM2b-Fc-fusion protein to U87 cells (blue) is not inhibited by 4 mM 
chondroitin sulfate C (CS-C, green). (f)  Binding of Siglec F-Fc to U87 cells (red) is not inhibited by 2 
mM  Chondroitin sulfate A (CS-A, light blue). (g and h) Graphic with means±SEM of fluorescent 
intensities of three different experiments of the binding of the TREM2b-Fc-fusion protein (g) and 
Siglec F Fc fusion protein (h) to concentrations of different glycosaminoglycans showing the strongest 
inhibitory effect. Control: secondary antibody (grey). The statistical analyzes compared the values of 
mean of fluorescence intensity from each single glycosaminlgycans to TREM2b-Fc fusion protein 
alone. Data are presented as mean±SEM, ANOVA - Bonferroni’s multiple comparasions using 
post-hoc test: ***p<0.001, **p<0.01 and NS: not significant. GAGs: Glycosaminoglycans. 
 
4.4.1 Chondroitin sulfate disaccharides inhibit the binding of TREM2b-Fc fusion 
protein to glioma cells 
The abilities of disaccharides DS-4S and DS-OS to bind to mouse TREM2b-Fc-fusion 
protein were examined by flow cytometry. The results showed that a concentration of 0.2 
mM of DS-4S can partially inhibit binding of mouse TREM2b-Fc-fusion protein to U87 
glioma cells. Whereas, 0.2 mM of DS-0S cannot inhibit the binding of mouse TREM2b-
Fc-fusion protein to glioma cells (Figure 4.5 a and b). 
Figure 4.5 – FACS analysis of the binding capacity of disaccharide 4 sulfate or disaccharide non-
sulfated to mouse TREM2b-Fc-fusion protein. (a) The TREM2b-Fc-fusion protein binds to U87 
cells (blue) and the binding of disaccharides 4 sulfate (DS-4S) to TREM2b-Fc fusion protein is 
partially inhibited after 0.2 mM DS-4S (orange).  (b) The binding of disaccharides non-sulfate (DS-
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0S) to TREM2b-Fc-fusion protein is not inhibited after incubation with 0.2 mM DS-0S (orange). The 
TREM2b-Fc fusion protein binds to U87 cells (blue). Control: secondary antibody control (grey). 
 
4.1.1. Analysis of TREM2 function in mouse microglia cell line 
 
Since specific ligands for TREM2 receptor remain unclear, one of the main goals was to find 
a new ligand for TREM2 and to understand the role TREM2 plays in microglia. For this, 
microglia cell line (ESdM) was analyzed for expression of TREM2 receptor.  Furthermore, 
TREM 2 expression under stimulation with CS-A or Disaccharides (DS-4S and DS-0s) at 
varying concentrations and time points was analyzed.  
 
4.1.2. Detection of TREM2 expression in ESdM microglial cell line 
 
To investigate the function of TREM2 in mouse microglia, embryonic stem cells derived 
microglial precursor cells (ESdM) were used. To detect TREM2 protein levels, flow 
cytometry and a specific mouse polyclonal antibody directed against TREM2 were used.  
ESdM cells were showing expression of TREM2 on their surface (Figure 4.6). Thus, data are 
proving that ESdM microglia cell line has an expression of TREM2 at protein leve. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6 – Flow cytometry analysis of TREM2 in ESdM. ESdM cells showed expression of 
TREM2 when stained with TREM2 antibody (blue). Isotype control (blue). Secondary antibody 
(grey). 
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4.1.3. Effects of chondroitin sulfate or chondroitin disaccharide sulfate stimulation on 
microglia cell line in terms of phagocytosis  
 
 
The phagocytic capacity of microglia after stimulation with possible ligands of TREM2 
receptor was analyzed. Initially, the phagocytosis assay was evaluated after stimulation of 
ESdM cells with different concentrations of CS-A (blue) (Fig. 4.7a) and during different time 
points (Fig. 4.7b).  The results indicate that 2 mM of CS-A led to a significant increase in 
ESdM phagocytosis capacity (38.9 ± 22.5 percentage units, p<0.001) when compared with 
untreated cells (black) (21.2 ± 2.3 percentage units, p<0.001; Figure 4.7 a). Two hours 
stimulation of microglia cells with 2 mM of CS-A showed significantly increases of beads 
phagocytosis (34.9 ± 5.2 percentage units, p<0.001) when compared with untreated cells (18.0 
± 3.7 percentage units, p<0.001; Figure 4.7 b).  
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Figure 4.7 – CS-A stimulates phagocytosis in a concentration and time point dependent way. (a) 
CS-A stimulates phagocytosis in concentration dependent pattern. Relative numbers of 
phagocytosis in ESdM cells were determined by flow cytometry. ESdM cells were incubated with 
TREM2 ligand CS-A in different concentration (0.1 mM, 0.2 mM, 0.4 mM, 1 mM, 2 mM, 4 mM and 
10 mM) and afterwards with beads. (b) CS-A stimulates phagocytosis in time dependent way. 
ESdM cells were incubated with the TREM2 ligand CS-A (2 mM ) for different time intervals ( 0.5h, 
1h, 2h, 4h, 8h, 16h and 24 h and then beads phagocytosis capacity was evaluated by flow cytometry. 
Data are presented as a mean±SEM. ANOVA - Bonferroni’s multiple comparasions using post-hoc 
test: ***p<0.001. 
4.4.2 Chondroitin sulfate disaccharide increases the phagocytosis  dependent on time 
and concentration  
DS-4S can bind to TREM2 and increases beads phagocytosis after stimulation with different 
concentrations (0.001 mM, 0.004 mM, 0.02 mM, 0.01 mM, 0.2 mM, 0.1 mM and 2 mM) and 
at different incubation times (30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 16 hours and 24 
hours). ESdM cells after stimulation with 0.02 mM (42.87 ± 3.8 percentage units, P<0.001) 
and 0.2 mM (52.3 ± 1.8 percentage units, p<0.001) of DS-4S for 1 hour show a significant 
increase in beads phagocytosis (orange), when compared with untreated cells (black) 0.02 
mM (11.2 ± 2.1 percentage units, p<0.001) and 0.2 mM 10 ± 3.6 percentage units, p<0.001) 
of DS-4S; Figure 4.8 a).  
After stimulation of microglia cells with 0.2 mM of DS-4S for different incubation times (30 
minutes 61.4 ± 10.4 percentage units, p<0.001), 1 hour (54.7 ± 7.7 percentage units, p<0.01), 
2 hours (0.0 ± 3.9 percentage units, p<0.01) 4 hours (43.5 ± 2.5 percentage units, p<0.01) and 
8 hours (53.1 ± 5.2 percentage units, p<0.001) showed significantly increases of beads 
phagocytosis when compared with untreated cells in respective times (30 minutes 17.0 ± 1.3 , 
p<0.001, 1 hour 10.4 ± 1.8 p<0.001 , 2 hours 24.3 ± 1.0, 4, p<0.01, 4 hours 22.1 ± 2.7, p<0.01 
and 8 hours 23.5 ± 1.7 percentage units, p<0.001; Figure 4.8 b). 
The non sulfated disaccharide DS-0S was also tested in ESdM cells with different 
concentrations and also at different time points of stimulation. The results are not shown here 
because no difference of beads uptake was observed between the timing and concentrations. 
In summay, the results here showed that the chondroitin sulfate can stimulate and increase the 
beads phagocytosis in microglia cell line. 
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Figure 4.8 – DS-4S stimulates phagocytosis in a concentration and time point dependent way. (a) 
DS-4S stimulates phagocytosis in concentration dependent pattern. Relative numbers of 
phagocytosis in ESdM cells were determined by flow cytometry. ESdM cells were incubated with 
TREM2 ligand CS-A in different concentration (0.001 mM, 0.004 mM, 0.02 mM, 0.01mM, 0.2 mM, 
0.1 mM and 2 mM) and afterwards during 30 minutes at 37 ºC with beads. (b) DS-4S stimulates 
phagocytosis in time dependent way. ESdM cells were incubated with the TREM2 ligand DS-4S 
(0.2 mM ) for different time intervals ( 0.5h, 1h, 2h, 4h, 8h, 16h and 24 h and then beads phagocytosis 
capacity was evaluated by flow cytometry. Data are presented as a mean±SEM. ANOVA - 
Bonferroni’s multiple comparasions using post-hoc test: ** p<0.01, ***p<0.001. 
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4.4.3 Effects of TREM2 knock down on beads phagocytosis  
To study the effect of TREM2 on microglial phagocytosis, we used a lentiviral strategy to 
knockdown TREM2. ESdM cells were transduced with 3 different lentiviral vectors for 
TREM2 knockdown (shTREM2 – plasmids 1, 2 and 3) or a control vector that expressed a 
short hairpin scrambled sequence (short hairpin control [shRNA control]).  
 
To confirm the knockdown, TREM2 gene transcripts were analyzed by RT-PCR. Indeed, a 
lower transcriptional level for TREM2 were detected in ESdM cells transduced with TREM2 
knockdown plasmids number 1 (0.17 ± 0.06, p<0.001), 2 (0.3 ± 0.06, p<0.001) and 3 (0.049 ± 
0.06, p<0.001) when compared with the shRNA control (1.2 ± 0.008, p<0.001; Figure 4.9 a). 
 
Cells were stimulated with different ligands of TREM2 of CS-A (2 mM), DS-4S (0.2 mM) 
and with DS-0S (0.2 mM) unsulfatedas a control. TREM2 KD P1, P2 and P3  receiving 
ESdM cells have not shown significant differences of beads phagocytosis after stimulation 
with 2 mM of CS-A, 0.2 mM of DS-4S or 0.2 mM of DS-0S when compared with untreated 
TREM2 P1, P2 and P3 knockdown ESdM cells. On the other hand, the shRNA scramble 
control cells (shRNA vector) shown significant increase of beads phagocytosis after 
stimulation with 2 mM of CS-A (55.1 ± 1.1 percentage units, p<0.001), 0.2 mM of DS-4S 
(56.2 ± 1.1 percentage units, p<0.001) or 0.2 mM DS-0S (57 ± 1.8 percentage units, p<0.001) 
when compared with untreated cells (36.5 ± 0.1 percentage units, p<0.001; Figure 4.9 b).  
 
In conclusion, these experiments prove that microglial cells in are dependent on expression of 
TREM2 receptor on the for beads up-take.  
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Figure 4.9 – Knockdown of TREM2 in ESdM. (a) RT-PCR analysis of cultured ESdM cells 
transduced either with a lentiviral vector producing short hairpin RNA specific for TREM2 (shRNA 
P1, P2 or P3) or irrelevant short hairpin RNAs (shRNA – vector). (b) Beads uptake after TREM2 
knockdown in ESdM cells. TREM2 knockdown in ESdM cells decreases beads phagocytosis even in 
the presence of chondroitin sulfate A and chondroitin sulfate disaccharides .The graphic represent 
mean± SEM of fluorescence intensity from three independent experiments,  Data are presented as 
mean±SEM, ANOVA Bonferroni’s multiple comparasions using post-hoc test: ***p<0.001. 
 
4.4.4  Effects of chondroitin sulfate A and chondroitin sulfate disaccharides on DAP12 
full length versus truncated  DAP12  on microglia 
DAP12 is the adaptor molecule of TREM2 and has an immunoreceptor tyrosine based 
activation motif (ITAM) (Paloneva et al., 2000).  
After stimulation of microglial cells with CS-A, beads phagocytosis was increased (Figure 
4.10 a). To prove the involvement of TREM2 receptor in phagocytosis, cells were stimulated 
with CS-A and DS-4S ligands of TREM2), using DS-0S as internal control. ESdM cells over-
expressing full length DAP12, ESdM cells having a truncated ITAM domain of DAP12 and 
ESdM control cells were stimulated with 2 mM of CS-A for 2 hours and with 0.2 mM of DS-
4S or DS-0S for 1 hour based on previous results.  
After stimulation of DAP12-overexpressing ESdM cells with CS-A (72.3 ± 1.0 percentage 
units, p<0.001) or DS-4S (71.4 ± 2.4 percentage units, p<0.001), show significant increase in 
beads phagocytosis was seen when compared with untreated treated control cells (GFP) (CS-
A: 64 ± 1.1, percentage units p<0.001, DS-4S: 61.2 ± 0.2 percentage units, p<0.001). ESdM 
cells having a truncated ITAM domain of DAP12 showed significant difference in beads 
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phagocytosis after stimulation with CS-A (16.9 ± 2.9, percentage units p<0.001), DS-4S (10.3 
± 0.8 percentage units, p<0.001) or DS-0S (13.8 ± 0.8 percentage units, p<0.001) when 
compared to treated control cells (GFP) (CS-A: 64.1 ± 1.1, p<0.001, DS-4S: 61.2 ± 0.2, 
p<0.001 and DS-0S: 51.3 ± 3.5 percentage units, p<0.001, respectively). The control cells 
(GFP) showed significant increase of beads phagocytosis after stimulation with CS-A (64.1 ± 
1.4 percentage units, p<0.001 in percentage units), DS-4S (61 ± 0.2 percentage units, 
p<0.001) or DS-0S (51.3 ± 3.5, percentage units p<0.001) when compared to untreated cells 
from the same group of cells (GFP) (35.2 ± 1.2, p<0.001, 32 ± 1.2, p<0.001 and 31 ± 1.3, 
percentage units p<0.001, respectively). In conclusion, these results show that the 
phagocytosis by microglial cell line is mediated via DAP12 (Figure 4.10).  
 
 
Figure 4.10 – Phagocytosis of beads is dependent on functional DAP12 expression and can be 
enhanced by CS-A or DS-4S.  Over-expression of DAP12 increases beads phagocytosis. ESdM GFP 
cells are controls cells, ESdM DAP12 Trunc cells have truncated ITAM domain and DAP12 Fl. Cells 
have overexpression of full length. Data are presented as mean±SEM. ANOVA-Bonferroni’s 
multiple comparasions using post-hoc test: ***p<0.001, NS: not significant. 
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4.4.5  Effects of chondroitin sulfate A and chondroitin sulfate disaccharides on 
microglia cells by analyses of pro- and anti- inflammatory cytokines 
ESdM cells were stimulated with 2 mM CS-A, 0.2 mM chondroitin sulfate disaccharide DS-
4S or 0.2 mM unsulfated disaccharide DS-0S for 30 minutes, 1 hour or 2 hours at 37 ºC.  
Afterwards, transcriptions of pro- and anti- inflammatory cytokines were analyzed by RT-
PCR. Values collected from these cells after stimulation with CS-A, DS-4S or DS-0S were 
normalized to those without stimulation.  
The results showed that 2 mM of CS-A significantly increases the transcription of the pro-
inflammatory cytokines IL-1ß and TNF-α after 1 and 2 hours of incubation with CS-A (IL-1ß, 
1 hour (62 ± 0.33 and 2 hours 352 ± 0.34; Fig. 4.11 a) and TNF-α, 1 hour (62.7 ± 0.47 and 2 
hours 353 ± 1.0: fig. 411 b) when compared with unteated cells 1 hour (0.52 ± 0.22 and 2 
hours 1.3 ± 0.3). The transcription of iNOS decreased significantly after 30 minutes and 
stayed decreased after 1 hour and 2 hours of incubation with 2 mM of CS-A when compared 
with untreated cells (1 hour (0.89 ± 0.03 and 2 hours 1.3 ± 0.3; Fig. 4.11 c), iNOS expression 
after 30 minutes (0.029 ± 0.06) 1 hour (0.049 ± 0.06) and 2 hours (0.58 ± 0.05) was observed 
Fig. 4.11 c. Stimulation with CS-A significantly increased the transcription of the anti-
inflammatory cytokine IL-10 during the different incubation with different times when 
compared with untreated cells (1.6 ± 0.6, 30 minutes 7.7 ± 0.5, 1 hour 3.8 ± 0.5 and 2 hours 
3.9 ± 0.6; Fig. 4.11 d). 
On the another hand, after stimulation of ESdM cells with 0.2 mM of DS-4S the gene 
expression of pro-inflammatory cytokines of IL-1ß, TNF-α and iNOS were increased. The 
expression of IL-1β was significantly increased after 30 minutes (9.9 ± 0.3; Fig. 4.12 a), but 
not significantly increased after 1 hour (1.8 ± 0.3) and 2 hours (1.3 ± 0.3) when compared to 
untreated cells (1.3 ± 0.6; Fig 4.12 a). The expression of TNF-α was also significantly 
increased 30 minutes (21.5 ± 0.3) after stimulation with DS-4S when compared to untreated 
cells (1.3 ± 0.3) and after 1 hour (6.9 ± 0.3) of stimulation, expression of TNF-α was 
significantly increased when compared to untreated cells (3.1 ± 0.3; Fig. 4.12 b). Interestingly, 
the expression of pro-inflammatory cytokines of IL-10 was significantly increased after 30 
minutes (20.1 ± 0.3) and 1 hour (3.9 ± 0.3) of stimulation with DS-4S in ESdM cells when 
compared with untreated cells (1.3 ± 0.3, 1.4 ± 0.03, respectively; Fig. 4.12 c). 
The results with stimulation of DS-0S on ESdM cells showed no strong effects on the 
production of proinflammatory cytokines during different times periods after stimulation.  The 
Results   
 
 
51 
 
transcription expression of IL-1β showed significant increase after stimulation for 30 minutes 
(0.8 ± 0.03) and 2 hours (0.7 ± 0.2) when compared to untreated cells (1.4 ± 0.3 and 0.9 ± 
0.03, respectively; Fig. 4.13 a). The transcription expression of TNF-α after stimulation with 
DS-0S was significantly increased after 30 minutes (0.8 ± 0.03) and 2 hours (1.3 ± 0.1) when 
compared to untreated cells (1.3 ± 0., 0.9 ± 0.03; Fig 4.13 b). The iNOS transcription 
expression showed significant increase after 30 minutes (0.8 ± 0.03) of stimulation when 
compared with untreated cells (1.3 ± 0.3: Fig. 4.13 c). Stimulation with DS-0S does 
significantly increase the transcription of the anti-inflammatory cytokine IL-10 during the 
different incubation with 30 minutes (0.4 ± 0.06) and 2 hours (1.3 ± 0.1) when compared with 
untreated cells (0.6 ± 0.03, 0.5 ± 0.03; Fig. 4.13 d). In the end, these results confirm that the 
sulfated groups of chondroitin sulfate are maybe involved in microglia phagocytosis mediated 
via TREM2 receptor. 
 
Figure 4.11 – Anti- and pro-inflammatory mRNA profile after stimulation of microglia cell line 
cells with CS-A. qRT-PCR was carried out to detected IL-1ß, TNF-α, iNOS and IL10 in ESdM cells 
after stimulation with 2 mM of CS-A during 30 minutes, 1 hour and 2 hours. (a) Microglia cell line 
show significantly increased of mRNA transcriptional level expression of IL-1ß after stimulation with 
2 mM of CS-A during 1 hour and 2 hours (grey) when compared with untreated cells (black). (b) 
Microglia cell line show significantly increased of mRNA transcriptional level expression of TNF-α 
after stimulation with 2mM of CS-A during 1 and 2 hours (grey) when compared with untreated 
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cells(black). (c) iNOS mRNA transcriptional level expression in microglia cell line show decreased 
when compared with untreated cells after 30 minutes, 1 hour and 2 hours of treatment with 2 mM of 
CS-A. (d) Treatment of microglia cell line with 2 mM of CS-A after 30 minutes, 1 hour and 2 hours 
increased transcription of anti-inflammatory cytokine IL-10. Data are presented as mean±SEM. 
ANOVA-Bonferroni’s multiple comparasions using post-hoc test: ***p<0.001, **p<0.01, * 
p<0.05 and NS: not siginificant. 
 
 
 
 
 
 
Figure 4.12 – Anti- and pro-inflammatory mRNA expression profile after stimulation of 
microglia cell line cells with DS-4S.  qRT-PCR to detected IL-1ß, TNF-α, iNOs and IL10 in ESdM 
cells ater stimulated with 0.2 mM of DS-4S during 30 minutes. (a) Microglia cell line show 
significantly increased of mRNA transcriptional level expression of IL-1ß after stimulation with 0.2 
mM of DS-4S during 30 minutes (grey) when compared with untreated cells (black). (b) Microglia cell 
line show significantly increased of mRNA transcriptional level expression of TNF-α after stimulation 
with 0.2 mM of DS-4S during 30 minutes and 1 hour (grey) when compared with untreated cells 
(black). (c) iNOS mRNA transcriptional level expression in microglia cell line show decreased when 
compared with untreated cells after 2 hours of treatment with 0.2 mM of DS-4S. (d) Treatment of 
microglia cell line with 0.2 mM of Ds-4S after 30 minutes and 1 hour significantly increased 
transcription of anti-inflammatory cytokine IL-10. Data are presented as mean±SEM. ANOVA - 
Bonferroni’s multiple comparasions using post-hoc test: ***p<0.001, **p<0.01, * p<0.05 ande 
NS: not siginificant. 
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Figure 4.13 – Anti- and pro-inflammatory mRNA expression profile after stimulation of 
microglia cell line cells with DS-0S.  qRT-PCR to detected IL-1ß, TNF-α, iNOs and IL10 in ESdM 
cells ater stimulated with 0.2 mM of DS-0S during 30 minutes. (a) Microglia cell line show 
significantly increased of mRNA transcriptional level expression of IL-1ß after stimulation with 0.2 
mM of DS-0S during 30 minutes and 2 hours (grey) when compared with untreated cells (black). (b) 
Microglia cell line show significantly increased of mRNA transcriptional level expression of TNF-α 
after stimulation with 0.2 mM of DS-4S during 30 minutes and 2 hours (grey) when compared with 
untreated cells (black). (c) iNOS mRNA transcriptional level expression in microglia cell line show 
decreased when compared with untreated cells after 30 minutes of treatment with 0.2 mM of DS-0S. 
(d) Treatment of microglia cell line with 0.2 mM of DS-0S after 30 minutes and 2 hours significantly 
increased transcription of anti-inflammatory cytokine IL-10. Data are presented as mean±SEM. 
ANOVA - Bonferroni’s-multiple multiple comparasions using post-hoc test: ***p<0.001, **p<0.01 
ande NS: not siginificant. 
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5. Discussion 
Past studies on microglial phagocytic activity were carried out mainly in cell culture systems 
using various approaches like application of fluorescent proteins and bacteria or yeast 
particles (Heneka et al., 2006; Mairuae et al. 2007; Koenigsknecht and Landreth, 2004). 
However, neonatal or immortalized microglia are not reflective of microglial properties in 
tissue environment. Recently, fluorescent microspheres were not only applied to primary 
microglia but also injected into the brain of prion diseased models (Hughes et al., 2010).   
One of the main characteristics of microglia is phagocytosis of either pathogens or of cells 
that underwent apoptosis and cellular debris during development and in pathology and 
regeneration  (Fourgeaud and Boulanger, 2007).  
In this project I aimed to find new ligands for microglial receptor TREM2, which until now, is 
yet to be described. Glycosaminoglycans from different sources and having different degrees 
of polymerization were tested by blocking the binding of mouse TREM2-Fc-fusion proteins to 
the glycocalyx of altered cells (glioma cells). Furthermore, the glycosaminoglycans were 
tested in their capacity to stimulate phagocytosis using fluorescent beads in culture of mouse 
microglia (ESdM – stem cell-derived microglia) cells with a normal or knocked down 
expression of TREM2.  
Therefore I investigated which chondroitin sulfate or chondroitin sulfate disaccharides could 
bind to TREM2-Fc-fusion protein and inhibit the binding to glioma cells. Interestingly, CS-A 
showed the better candidate substance can binds to TREM2 receptors. The characterization of 
the function of CS-A in microglia cells showed that CS-A can increase the beads 
phagocytosis. Knockdown of TREM2 in microglia decreased the beads phagocytosis in ESdM 
cells after stimulation with ligands of TREM2. 
Couple of years ago it was reported that the microglial TREM2/DAP12 complex is involved 
in phagocytosis of apoptotic neurons without  inflammation (Takahashi et al., 2005). The 
immune  receptor TREM family was discovered by the group of Prof. Colonna and was  
proven to be expressed together with DAP12 in neutrophils and monocytes (Bouchon et al., 
2000). To facilitate a better understanding of the involvement of microglial receptor TREM2 
and its co-adaptor molecule DAP12 in phagocytosis after stimulation with CS-A, ESdM cells 
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overexpressing full length DAP12, truncated DAP12, or control cells were used. Results 
showed that CS-A increases microglia phagocytosis in a time and concentration dependent 
manner. Moreover, ESdM cells have less capacity to take up the fluorescent beads compared 
to the control group even in the presence of CS-A, proving the specificity of CS-A-triggered 
activation of microglia via the TREM2/DAP12 complex. 
Thus, the present study brings new evidence that the ligand for microglial receptor TREM2 
could be a member of chondroitin sulfate family (CS-A). Furthermore, data demonstrate an 
involvement of the chondroitin sulfate ligand in the phagocytosis of microglial cells, 
proposing a mechanisms that might be used for therapy in the future in neurodegenerative 
disease.  
5.1 Binding of TREM2 to chondroitin sulfate group or chondroitin sulfate 
disaccharides 
Intially, TREM2 was found to bind broadly to bacteria, and that binding was inhibited by 
anionic glycans (Daws et al., 2003). It was demonstrated that TREM2 interacts with 
endogenous ligands (Hsieh et al., 2009),. and promotes phagocytosis of apoptotic neurons 
without activation of TNFα transcription (Takahashi et al., 2005). However an endogenous 
apoptotic material epitope that can be recognized by TREM2 has not been identified.   
Until now, no work in literature has demonstrated binding of CS family to TREM2 microglial 
receptor. However CS is known to bind other receptors such as CD36 and CD44, that are 
expressed on macrophages (Ruffell et al.). The report here demonstrats that CS family is a 
new ligand for TREM2 receptor and the best CS subunit that can bind to TREM2 is CS-A. 
With the mention that CS-C showed no binding to TREM2 receptor. Interestingly, a report 
indicated that another member of the TREM receptor family, TREM-like 4 (Treml4), also 
recognizes apoptotic cells (Hemmi et al., 2009).  
In this thesis, it was shown that the mouse TREM2-Fc-fusion protein can recognize specific 
ligands expressed on the cellular membrane of CHO, GL261, SMA-MS and U87 cells. The 
glioma cells might have modifications on the glycocalyx, where the TREM2 might bind to 
(Daws et al., 2003). 
The glycosaminoglycans families have been used for therapy in several inflammatory 
diseases, where CS is a sulfated glycosaminoglycan (GAG) composed of linear chains that are 
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formed by repeated disaccharide (Rolls et al., 2006). Disaccharides are polymerized into long 
chains and modified by sulfation. CS disaccharides can be monosulfated at positions 4 or 6 
(CS-A and CS-C, respectively) or disulfated at position 2 and 6 (CS-D) and positions 4 and 6 
(CS-E). CS is usually found attached to proteins, as part of a glycosaminoglycan and 
participates in the formation of the extracellular matrix. CS is considered to be a major 
inhibitor of axonal regeneration and is known to participate in activation of inflammatory 
responses (Rolls et al., 2006). In experimental autoimmune encephalomyelitisCS-C promotes 
recovery and neuronal survival, effects that were associated with inhibition of NF-kB nuclear 
translocation (Vallieres and du Souich). Our results show that CS-C can not bind to TREM2 
receptor, but CS-A can bind and activate it. In studies using a combined in vivo model of 
chronic arthritis and atherosclerosis, intraperitoneal bovine CS reduced NF-kB nuclear 
translocation in peripheral blood mononuclear cells (Vallieres and du Souich; Herrero-
Beaumont et al., 2008) and patienst who received treatment with 1000mg/Kg/day of CS orally 
for 63 days were partially prevented from developing osteoarthritis (Seed et al., 2009). The 6-
sulfated disaccharide (chondroitin sulfate C) induces axonal growth and activated microglia to 
adopt a neuroprotective phenotype (Rolls et al., 2004). Thus, disaccharidic degradation of CS 
participates in the modulation of the inflammatory responses and could, therefore, promote 
recovery in immune-induced neuropathologies of the CNS, such as experimental autoimmune 
encephalomyelitis (EAE) and experimental autoimmune uveitis (EAU) (Rolls et al., 2006). It 
has been shown that disaccharides obtained from CS markedly alleviate the clinical symptoms 
of EAE and attenuate T cell motility. Furthermore, there is decreased secretion of cytokines 
such as interferon-gamma and TNFα (Rolls et al., 2006).  
Another study has shown that DS-stimulated microglia possessed increased beads phagocytic 
capacity but lacked direct cytotoxic effects such as secretion of NO (Ebert et al., 2008). 
Analysis by microarray showed up-regulation of 29 genes that had anti-inflammatory  and 
neuroprotective functions, when microglial cells were stimulated with DS, but when microglia 
cells were stimulated with IFN-γ the 25 genes were down-regulated (Ebert et al., 2008).  This 
study is in agreement with my results, where I have demonstrated that chondroitin sulfate 
disaccharides can bind to TREM2 receptors. Two different disaccharides were used in my 
study, disaccharides sulfated in position 4 (DS-4S) and as control - disaccharides which are 
not sulfated (DS-0S). The non-sulfated disaccharides showed no binding to TREM2 receptor. 
This means that the sulfate group can interfere with the binding to TREM2 receptor. But it is 
still unclear how the disaccharides can bind to TREM2.   
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In future it will be interesting to perform new experiments with different groups of 
disaccharides provided from CS-C (DS-6), from CS-D (DS-2,4) and from CS-E (DS-4,6) to 
confirm the binding of disaccharides to TREM2 dependent on the sulfate-group position. 
Another interesting question to be analyzed in the future is to elucidate whether chondroitin 
sulfate D (CS-D) or chondroitin sulfate E (CS-E) can bind to TREM2 receptor.  
5.2 TREM2 receptor binding of chondroitin sulfate group from the glycocalyx of 
glioblastoma cells 
The enzyme ChABC has been demonstrated to be an effective treatment to promote axonal 
regeneration after spinal cord injury. In the cerebellum, degradation of CS GAG chains by 
treatment with ChABC promoted structural plasticity of Purkinje axons (Garcia-Alias et al., 
2006). Recently, it has been shown after C4 dorsal spinal cord injury that rats that received 
both ChABC and task-specific rehabilitation showed the best recovery in skilled paw (Wang 
et al., 2007). The ChABC has been used for treatment of recovery in different 
neurodegenerative diseases. In spinal cord injury, treatment with ChABC degraded CS-GAG 
at the injury site, up-regulated a regeneration-associated protein in the injured neurons, and 
promoted regeneration. 
Here I investigated whether TREM2 receptor could still bind to glioma cells after removal of 
the CS group of the glycocalyx on cells treated by chondroitinase (ChABC). The results 
showed that after pre-treatment of glioma cells with ChABC, the binding of TREM2 to U87 
cells was partially inhibited. In contrast, when the glioma cells were treated with sialidase, an 
enzyme that could cleave the sialic acid groups of the glycocalyx of the target cells, no change 
of TREM2 binding to glioma cells was observed. As known the U87 cells is a human primary 
glioblastoma cells and have alter glycocalix where expressed alterated amounds of 
glycosaminoglycans. These results confirmd that CS groups are present on the glycocalyx of 
U87 glioma cells and can be digested and removed by chondroitinase ABC and consequently 
influence the binding of TREM2 receptor to U87 cells. This also suggests that the new ligand 
of TREM2 receptor is chondroitin sulfate and not another component of the extracellular 
matrix of glioma cells.  
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5.3 TREM2 is not dependent on removal of sialic groups of the glycocalyx of glioma 
cells 
Sialic acid is neuraminic acid, a monosaccharide with a nine-carbon backbone (Varki and 
Schauer, 2009). Sialic acids are found widely distributed in animal tissues and to a lesser 
extent in other organisms, ranging from plants and fungi to yeasts and bacteria, mostly in 
glycoproteins and gangliosides (Schauer, 2000). They are found at the end of sugar chains 
connected to the surfaces of cells and soluble proteins (Schauer, 2000). Here I found that 
sialic acid can not be recognized by TREM2. This was confirmed after treatment of glioma 
cells with sialidase did not change the binding capacity of the TREM2 to glioma cells.   
5.4  Analysis of TREM2 function in mouse microglia cell line 
Microglia have been implicated as active contributors to neuronal damage in 
neurodegenerative diseases, in which the over-activation and dysregulation of microglia might 
result in serious damage to the CNS and production of neurotoxic components. The microglia 
cells can produce pro-inflammatory cytokines and reactive oxygen species.  Microglia are 
assumed to remove synapses in the developing brain and take part in neuronal pruning in the 
postnatal brain. 
To mimic the in vivo neuro-inflammatory situation, the ESdM cell culture was stimulated with 
CS-A and the capacity to take up beads by phagocytosis was analyzed. Data obtained showed 
an increase of beads phagocytosis after stimulation with CS-A compared to unstimulated 
ESdM cells. The ESdM microglial cells are well known to phagocytose cellular debris during 
inflammation in CNS (Napoli et al., 2009). The analysis in vitro showed that ESdM cells 
stimulated with CS-A demonstrated activation of TREM2 signaling leading to increased 
phagocytosis. 
Next, knockdown of TREM2 receptor in ESdM was achieved by lentiviral transduction. 
TREM2 knockdown ESdM decreased the beads phagocytosis when compared to the control.  
The hypothesis investigated within this thesis is that TREM2 expressed on microglial cells 
bind to CS-A and act further via ITAM motifs of DAP12 increasing microglial phagocytosis 
capacity. The results confirm this hypothesis. Indeed, ESdM cell line expressed TREM2 and 
bound CS-A leading to increased phagocytosis via DAP12. All these data indicate that 
Discussion   
 
 
59 
 
TREM2 might be important for clearance of cellular debris and prevention of 
neurodegenerative processes.  
Recently, it was demonstrated that TREM2 deficiency results in impaired and delayed 
osteoclasts differentiation with reduced bone resorption capability in vitro (Otero et al., 2010). 
Furthermore, lentiviral vectors were successfully used for specific knockdown of TREM2 
gene transcripts by small hairpin RNAs in ESdM cells.  These results suggest that TREM2 
deficiency or knockdown can dysregulate and reduce microglial phagocytosis, which can 
affect the inflammatory progress. 
Another study demonstrated that disacchrides have a protective effect during the development 
of neurodegenerative diseases. They showed that disaccharides stimulate the production of 
anti-inflammatory cytokines, but did not demonstrate how this small molecule could be 
involved in this mechanism. I now demonstrate, in this study, that the disaccharides can bind 
TREM2 receptor. I stimulated the ESdM cells with disaccharides sulfated in position four 
(DS-4S) and with disaccharides which were not sulfated (DS-0S).T he sulfated disaccharides 
can increase beads phagocytosis when compared to the control cells. That suggests a 
protective effect of disaccharides, since TREM2 activated by disaccharides increases 
phagocytosis and might induce the production of anti-inflammatory cytokines.  
However, I also tested the capacity of ESdM microglial cells to produce anti and pro 
inflammaotry cytokines after stimulation with the ligands of TREM2 (DS-4S, DS-0S and CS-
A). Interestingly, I confirmed what has been shown before in literature, namely that 
glycosaminoglycans have both protective and deleterious effects. MRNA level of pro-
inflammatory cytokines (IL-1ß, TNF-α and iNOS) and an anti-inflammatory cytokine (IL-10) 
after stimulation with CS-A were increased. It is known that cytokines play a potential role in 
neurodegenerative diseases, when microglia remain in a chronically activated state. Direct 
injection of the cytokines IL-1α, IL-1β and TNF-α into the CNS resulted in local 
inflammatory responses and neuronal degradation. This is in contrast with the potential 
neurotrophic (inducing growth of neurons) actions of these cytokines during acute 
neuroinflammation (Willenborg and Staykova, 2003). It is known that the microglia 
population can be neuroprotective by degrading amyloid-beta plaques in AD by complement 
receptor (Crehan et al, 2012.). Stress models in murine found that microglia mainly recruit 
macrophages from the periphery that then transform into phagocytes in the brain (Wohleb et 
al., 2013). Therefore most of the phagocytes that were associated with plaques in the mouse 
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brain came from the bone marrow (A. R. Simard and S. Rivest, 2004). These findings show 
that microglia are committed to an inflammatory response with a lower phagocytotic capacity 
than newly recruited phagocytes. In mouse models of AD it was demonstrated that anti-
inflammatory drugs like minocycline improve cognitive functions and reduce the activation of 
microglial cells, but do not alter the amyloid plaques deposition and distribution (R. Fan, F. 
Xu, M. L. Previti, J. Davis, 2007). Therefore it is believed that an acute neuroinflammatory 
response is generally beneficial to the CNS, since it tends to minimize further injury and 
contributes to repair of damaged tissue. The opposite is the case for a chronic stimulation: 
chronic neuroinflammation is most often detrimental and damaging to nervous tissue. Thus, 
whether neuroinflammation has beneficial or harmful outcomes in the brain may depend 
critically on the duration of the inflammatory response. The progressive deposition of amyloid 
in AD disease might provide a chronic stimulus to microglial cells. Also the chemotactic 
functions of amyloid-β to attract microglia contribute further to the ongoing inflammatory 
process (Lue et al., 2001). 
 Nasu-Hakola disease, also referred to as polycystic lipomembranous osteodysplasia with 
sclerosing leukoencephalopathy (PLOSL) is a rare recessive human genetic disorder (Verloes 
et al., 1997; Bianchin et al., 2004). Nasu-Hakola disease is characterized by early onset 
cognitive dementia and bone cysts (both evident by the third decade). Individuals with this 
disease die by thefourth or fifth decade of life. Seminal studies by Peltonen and colleagues 
identified loss of function mutations in two separate genes as the causes of this rare disorder: 
namely, TREM2 and DAP12, also referred to as killer-cell activating receptor-associated 
protein (KARAP) and TYROBP (Paloneva et al., 2000; Paloneva et al., 2002; Klunemann et 
al., 2005). 
TREM2 is an orphan receptor that has recently been implicated in limiting the pro-
inflammatory activation state of macrophages and promoting expression of molecules 
associated with presenting antigen to T-lymphocytes (Bouchon et al., 2000; Bouchon et al., 
2001; Daws et al., 2001; Daws et al., 2003). TREM2 belongs to the class of receptors lacking 
an intracellular signaling tail. To date, only a single molecule has been identified that serves to 
mediate TREM2 triggered intracellular signaling: DAP12 (Lanier et al., 1998; Lanier and 
Bakker, 2000; Daws et al., 2001; Prada et al., 2006).  
Two types of data suggest that TREM2 and DAP12 may play either a direct or indirect role in 
oligodendrocyte development and function. First, histological analysis of adult CNS tissue 
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from DAP12 knock-out mice in studies by two separate groups revealed modest, diffused 
hypomyelination in anterior brain regions that was associated with substantial reductions in 
CNS microglia (Kaifu et al., 2003; Roumier et al., 2004; Nataf et al., 2005). Subsequent gene 
profiling studies of CNS mRNA isolated from DAP12KO mice by a third group revealed 
decreased expression of selected myelin transcripts (Kiialainen et al., 2007). These data were 
initially interpreted to suggest a fundamental role for microglia in supporting oligodendrocyte 
development and/or myelination. In support of this hypothesis, TREM2 and DAP12 
expression near white matter tracts has been detected by in situ hybridization analysis in post-
natal developing brain (Kiialainen et al., 2005).  
In this study I showed that the activation of phagocytosis in ESdM cells after stimulation with 
ligands of TREM2 is dependent on the co-receptor DAP12. For this analysis, different ESdM 
cell lines were developed by lentiviral transduction to overexpress either full length functional 
DAP12, truncated non-functional DAP12 (in which the ITAM signaling motif was deleted) or 
a control vector. The backbone vector was designed with a GFP expressing cassette.  
After stimulation of ESdM with CS-A, DS-4S or DS-0S and incubation with beads, ESdM in 
which the ITAM signaling motif was deleted showed decreased capacity to take up beads, 
while the ESdM with DAP12 overexpression showed increased phagocytosis of beads 
compared with control cells. This finding confirms that the DAP12 co-receptor is involved in 
phagocytosis of microglia cells via TREM2 receptor ligands.  
In conclusion, in this work a new ligand for TREM2 stimulation in vitro was identified. CS-A 
and chondroitin sulfate disaccharides (DS-4S) activated phagocytosis of microglial cells via 
TREM2 and were dependent of DAP12-ITAM signaling. Clearance of cellular debris via CS 
acting on TREM2 might fulfill a protective role in the central nervous system (CNS). 
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